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2.  Abstract 
Systemic amyloidosis is the exemplar infiltrative, extracellular disease. Although it is 
a multi-organ disorder, cardiac involvement drives prognosis. Survival is worst in the AL 
amyloidosis subtype. It can affect any age and any race. There is no direct test for amyloid 
burden and there is no treatment for amyloidosis, there is only treatment for the underlying 
condition. Earlier diagnosis permits prompt treatment and improves survival.  
A number of imaging modalities exist to non-invasively detect cardiac disease but all 
have  limitations.  Cardiovascular  magnetic  resonance  (CMR)  with  late  gadolinium 
enhancement (LGE) imaging provides the highest sensitivity for early detection. However, 
this  also  has  its  shortcomings.  There  is  currently  no  non-invasive  method  of  directly 
measuring amyloid burden in the extracellular space. New therapies are pending – but their 
development  needs  new  surrogate  endpoints  and  new  tests  are  therefore  desperately 
needed. T1 mapping permits tissue abnormalities to be directly visualised in a simple scan – 
the  colour  changes  being  instantly  recognisable,  either  before  contrast  (pre  contrast  or 
native  T1  mapping)  or  after,  when  the  myocardial  extracellular  volume  (ECV)  can  be 
measured.  
In a collaboration between the National Amyloidosis Centre and the Heart Hospital, I 
explored the possibility and potential that T1 mapping might measure cardiac (and other 
organ) involvement in systemic amyloidosis using EQ-MRI.  
In early clinical exploration in systemic AL amyloid, I showed that native myocardial 
T1 was elevated in cardiac amyloidosis and tracked disease, particularly early disease. Mean 
pre  contrast  myocardial  T1  as  measured  by  ShMOLLI  was  higher  in  patients  at  1086  ± 
90msec, compared to healthy volunteers of 958 ± 20msec (P<0.001). Myocardial T1 times 
showed a stepwise elevation as the probability for cardiac involvement increased: 1009 ± 
31msec without cardiac involvement, 1048 ± 48msec with possible cardiac involvement, 
1140 ± 61msec with definite cardiac involvement (P<0.001).  
Using contrast to measure the ECV, I was able to non-invasively and directly measure 
the amyloid burden in the heart for the first time. Mean cardiac ECV was greater in patients 
compared to healthy volunteers with a wider range (0.44 ± 0.12 vs 0.25 ± 0.02, P<0.001) and Page 4 of 150 
tracked pre-test probability of cardiac involvement by conventional parameters (P<0.001). 
ECV also tracked conventional measures of disease severity and correlated with survival 
with a median ECV of 0.45 being the best model for assessing survival: HR 3.84 (1.53 – 9.61), 
P=0.004. I demonstrated good reproducibility of the technique with an ICC of > 0.9 for both 
the FLASH IR and ShMOLLI techniques of T1 mapping and good agreement of ECV derived 
from both techniques. In pilot studies, I also demonstrated by serial scanning that changes 
(including regression) over time could be measured. 
In other organs, I showed that the amyloid burden could be measured and was 
higher in amyloidosis compared to healthy volunteer: ECV 0.32 vs 0.29 (P<0.001) for liver, 
0.39 vs 0.34 (P<0.001) for spleen and 0.16 vs 0.09 (P<0.001) for skeletal muscle. These ECVs 
also tracked current conventional measures of disease severity by nuclear scintigraphy.  
These results demonstrate that the interstitial volume in patients with systemic AL 
amyloidosis can be measured non invasively in the heart, liver, spleen and skeletal muscle 
and  that  this  correlates  with  existing  markers  of  disease  and  survival.  Pre  contrast 
myocardial T1 was a good alternative measure for the heart.  
In conclusion, the work in this thesis has enabled a deeper understanding of cardiac 
amyloidosis, disease processes and stages. It has pioneered a new prognostic marker that is 
also  able  to  identify  some  patients  with  cardiac  involvement  that  were  previously 
unrecognised. Novel subtypes are now recognised (e.g. cardiac amyloidosis with no LVH) 
and  it has  also  allowed  direct  quantification of  the  liver  and  spleen.  ECV  is  a  new  and 
powerful biomarker that has already been adopted by industry allowing development of 
new therapies and providing hope that an end to the scourge of this disease is near.    Page 5 of 150 
3.  Abbreviations 
6MWT   6 Minute Walking Test 
AA    Amyloid (serum amyloid A) 
ACE-i    Angiotensin Converting Enzyme inhibitor 
AF    Atrial Fibrillation 
AFD    Anderson Fabry’s disease 
AHA    American Heart Association 
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DCM    Dilated Cardiomyopathy 
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HR    Hazard Ratio 
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ICC    Intraclass Correlation Coefficient 
ICD    Implantable Cardioverter Defibrillator 
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IVRT    Isovolumic Relaxation Time 
KM    Kaplan Meier 
LA    Left Atrium 
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MI    Myocardial Infarction 
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MRI    Magnetic Resonance Imaging 
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NNE    Nearest Neighbour Estimator 
NT-proBNP  Nitrogen-Terminal Brain Natriuretic Peptide 
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PET    Positron Emission Tomography 
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SAA    Serum Amyloid A 
SAP    Serum Amyloid P 
SASHA   Saturation-recovery Single-shot Acquisition  
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SD    Standard Deviation 
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TD    Trigger delay 
TDI    Tissue Doppler Imaging 
TE    Echo Time 
TI    Inversion Time 
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5.  Aims & Objectives 
  This  thesis  investigates  the  use  of  novel  methods  in  cardiovascular  magnetic 
resonance  (CMR)  for  the  investigation  of  the  extracellular  space  of  multiple  organs  in 
systemic amyloidosis. As in all science, it is built on the work of others – key methods were 
developed at Heart Hospital by my colleagues: (a) Dr Andrew Flett (UCL MD (Res), 2012) 
who designed and validated the use of EQ-CMR to measure myocardial fibrosis in aortic 
stenosis and hypertrophic cardiomyopathy; and (b) Dr. Daniel Sado (UCL MD (Res), 2013) 
who explored the role of ECV measurement (again for fibrosis) across a variety of cardiac 
diseases. My thesis built on this, but in amyloidosis. 
The aims are: 
1)  To investigate new potential markers of myocardial abnormality - ECV and native 
myocardial T1 measurement in cardiac amyloidosis, comparing the results to other 
clinical markers of disease severity. 
2)  To translate these methods to other organs - the liver, spleen and skeletal muscle in 
patients with systemic amyloidosis. 
3)  To improve ECV and T1 measurement techniques in CMR allowing quicker, more 
reproducible assessment for clinical delivery and as a surrogate endpoint for clinical 
trials 
4)  To create new hypotheses and aid in the recruitment and training of new 
researchers to continue this work, concurrently presenting and publishing the 
results, with the overall aim of bringing therapy and understanding of amyloid a step 
closer for patients; a step closer to improved outcomes for patients. 
   Page 19 of 150 
6.  Introduction 
This chapter is based on the publication below:
1 
Banypersad SM,  Moon  JC,  Whelan  C,  Hawkins  PN,  Wechalekar  AD.  Updates  in  cardiac 
amyloidosis: a review. J Am Heart Assoc. 2012 Apr;1(2):e000364 
My contribution was to research the material and write the paper. 
 
6.1  WHAT IS AMYLOIDOSIS?: 
Amyloidosis  is  a  generic  term  that  refers  to  the  extracellular  deposition  of 
autologous protein in an abnormal, insoluble β-pleated sheet, fibrillary conformation i.e. as 
amyloid fibrils. More than 30 proteins are known to be able to form amyloid fibrils in vivo, 
which  cause  disease  by  progressively  damaging  the  structure  and  function  of  affected 
tissues.
2  Amyloid deposits  also  contain  minor non-fibrillary  constituents  including  serum 
amyloid  P  component  (SAP),  apolipoprotein,  connective  tissue  components  such  as 
glycosaminoglycans (GAGS) and collagen, and basement membrane components such as 
fibronectin and laminin.
3-7 Amyloid deposits can be massive and cardiac or other tissues may 
become substantially replaced.  
Amyloid  fibrils  bind  Congo  red  stain,  yielding  the  pathognomonic  apple-green 
birefringence  under  cross-polarized  light  microscopy  that  remains  the  gold  standard for 
identifying amyloid deposits.  Further staining with immunohistochemistry is performed to 
subtype into the 2 main types which affect ventricular myocardium, light chain amyloid (AL) 
and transthyretin amyloid (ATTR) (see figure 1).  
Data  regarding  the  molecular  mechanisms  at  work  in  the  extracellular  space  is 
rapidly  accumulating.  Autopsy  studies  of  ventricular  myocardium  reveal  homogeneous, 
eosinophilic deposits separating the muscle fibres and amorphous hyaline deposits that are 
predominantly seen in the expanding extracellular space.
8 Molecular chaperones, such as 
clusterins,  have  been  found  to  be  over-represented  in  electron-microscopy  analysis  of 
cardiac biopsies in both AL and ATTR Amyloidoses.
9 Page 20 of 150 
 
Figure 1: An endomyocardial biopsy of a patient with cardiac AL amyloidosis stained as follows: (A) 
Congo Red only; (B) Apple-green birefringence under cross-polarized light; (C) Congo Red with 
lambda overlay (negative); (D) Congo Red with kappa overlay (positive). 
 
Studies of matrix metalloproteinases and their tissue inhibitors have suggested a 
direct  effect  of  the  activation  of  proteolysis  in  the  extracellular  matrix  by  circulating 
immunoglobulin light chains.
10  This may explain the long recognised observation that in 
primary AL amyloidosis, even mild to moderate ventricular thickening can cause significantly 
debilitating  symptoms  whereas  the  patient  with  an  equivalent  wall  thickness  in  ATTR 
amyloid is often asymptomatic.
11  
 
6.2  WHAT IS SYSTEMIC AMYLOIDOSIS?: 
Systemic  amyloidosis  is  the  exemplar  of  a  purely  extracellular  disease;  it  is  a 
relatively rare multisystem disease caused by the deposition of misfolded protein in various 
tissues and organs, causing organ dysfunction through interstitial expansion. It may present 
to almost any specialty and diagnosis is frequently delayed.
12  There are several different 
types of amyloid. As previously mentioned, the ventricles are primarily affected by AL and 
ATTR types; ATTR amyloid is further sub-divided into Senile Systemic Amyloidosis (SSA) and 
variant ATTR (see sections 6.3.2 and 6.3.3 later in this thesis).  Page 21 of 150 
Clinical phenotype varies greatly between different types of amyloidosis, and even 
the cardiac presentation has a great spectrum.  The incidence of amyloidosis is uncertain, 
but it is thought that the most frequently diagnosed type, AL amyloidosis, has an annual 
incidence of 6-10 cases per million population in the UK and US.  Wild type transthyretin 
(TTR) amyloid deposits, which predominantly accumulate in the heart, are very common at 
autopsy in the elderly and whilst the associated clinical syndrome known as senile systemic 
amyloidosis is diagnosed rarely in life,
13 there is increasing evidence that this disorder is 
much  under-diagnosed,  and  that  with  increasing  longevity  and  improved  diagnostic 
methods, it may be identified as a substantial public health problem.   
Key ‘red flags’ to the diagnosis of possible systemic amyloidosis include: nephrotic 
syndrome, autonomic neuropathy (postural hypotension, diarrhoea), soft tissue infiltration 
(macroglossia, carpal tunnel syndrome), cutaneous bleeding (periorbital, gastrointestinal), 
malnutrition/cachexia  and  genetic  predisposition  (family  history/ethnicity).  Other  organ 
involvement, particularly in AL amyloidosis, may cloud the cardiac presentation (nephrotic 
syndrome, autonomic neuropathy, pulmonary or bronchial involvement). Table 1 on the 
next page gives an outline of the clinical phenotype of the common amyloid subtypes.  Page 22 of 150 
Amyloid type  Precursor 
protein 
Typical  decade  
of presentation 
Cardiac 
involvement 
Other organ 
involvement 
Treatment  Prognosis (median 
survival) 
Primary (AL) 
Amyloidosis 
Monoclonal 
light chain 
 6
th  to 7
th decade 
(but can be any) 
40-50%  Renal, liver, soft tissue, 
neuropathy 
Chemotherapy or 
ASCT 
48 months but 8 months 
for advanced stage disease.  
Transthyretin Amyloidosis: consisting of: 
Senile 
Systemic (SSA) 
Wild-type TTR    70 years   Almost all cases  carpal tunnel syndrome  Supportive 
 
7-8 years  
ATTR (V30M)  Variant TTR    3
rd or 4
th decade    Uncommon   Peripheral and autonomic 
neuropathy 
Liver transplantation   Good with liver transplant 
for V30M  
ATTR (T60A)  Variant TTR  6
th decade   Up to 90% by 
diagnosis 
Peripheral and autonomic 
neuropathy 
Liver transplant 
possible in selected 
Variable with liver 
transplant 
ATTR Ile 122  Variant TTR    6
th – 7
th decade   Almost all cases  carpal tunnel syndrome  Supportive  7-8 years 
Apolipoprotein A1 
(ApoA1) 
Variant 
apolipoprotein 
6
th – 7
th decade  Rare  Predominantly renal  Renal (+/- liver) 
transplant 
Usually slowly progressive 
(years) 
Secondary (AA) 
amyloidosis 
Serum amyloid 
A (SAA) 
Any  Rare  Renal, liver  Treat underlying 
condition 
Good 
Atrial natriuretic 
peptide (ANP) 
ANP  70 years or older  All cases (uncertain 
significance) 
None reported  Not needed  - 
Table 1: summarising the pathology, presentation and management of different amyloid typesPage 23 of 150 
6.3  CARDIAC DISEASE: 
Ventricular  cardiac  involvement  is  a  leading  cause  of  morbidity  and  mortality, 
especially  in  primary  (AL)  amyloidosis  and  in  both  wild  type  and  hereditary  transthyretin 
amyloidosis.  The heart is also occasionally involved in acquired AA amyloidosis, other rare 
hereditary types, and there is a specific atrial subtype (ANP).   
Cardiac  amyloidosis  affecting  the  ventricles,  irrespective  of  type,  presents  as  a 
restrictive  cardiomyopathy  caused  by  interstitial  expansion  due  to  the  amyloid  and  is 
characterized by progressive diastolic and subsequently systolic biventricular dysfunction and 
arrhythmia.
12 Initial presentations may be cardiac with progressive exercise intolerance and 
heart failure.  Pulmonary oedema is not common early in the disease process,
14 but pleural 
and pericardial effusions and atrial arrhythmias are often seen.
15, 16  Syncope is common and a 
poor prognostic sign.
17 It is typically exertional or post-prandial as part of either restrictive 
cardiomyopathy, sensitivity to intravascular fluid depletion from loop diuretics combined with 
autonomic neuropathy, or conduction tissue involvement (AV or sinus nodes) or ventricular 
arrhythmia.
18-20 The latter may rarely cause recurrent syncope.   
Disproportionate  septal  amyloid  accumulation  mimicking  hypertrophic  cardio-
myopathy (HCM) with dynamic left ventricular outflow tract obstruction
21-24 is rare, but well 
documented.    Myocardial  ischaemia  can  result  from  amyloid  deposits  within  the 
microvasculature.
25, 26 Atrial thrombus is common, particularly in AL amyloidosis, sometimes 
before atrial fibrillation (AF) occurs.
27 Intracardiac thrombus can embolise, causing transient 
ischaemic  attacks  or  strokes  and  may  be  an  early  or  even  presenting  feature.
28  
Anticoagulation  is  therefore  important  in  the  appropriate  clinical  situation  but  careful 
consideration has be given in patients with extensive systemic AL amyloidosis who may have 
an    elevated  bleeding  risk  seen  due  to  Factor  X  deficiency  or  in  some  cases  with  GI 
involvement.
29   
 
6.3.1  AL Amyloidosis: 
AL  amyloidosis  is  caused  by  deposition  of  fibrils  composed  of  monoclonal 
immunoglobulin  light  chains,  and  is  associated  with  clonal  plasma  cell  or  other  B-cell 
dyscrasias. The fibrils in AL amyloidosis are derived from the variable region of lambda light Page 24 of 150 
chains in approximately 75% of cases, and kappa in the remainder.
30 In approximately 10% of 
cases, the disorder overlaps with overt multiple myeloma. 
The spectrum and pattern of organ involvement is very wide, but cardiac involvement 
occurs in half of cases and is sometimes the only presenting feature.
31 Cardiac AL amyloidosis 
may be rapidly progressive. Low QRS voltages, particularly in the limb leads are common.  
Thickening of the left ventricular wall is typically mild to moderate, and is rarely greater than 
18mm, even in advanced disease.  Cardiac AL amyloid deposition is accompanied by marked 
elevation  of  the  biomarkers  brain  natriuretic  peptide  (BNP,  specifically  NT-proBNP)  and 
cardiac troponin, even at an early stage.  The right heart failure is often exacerbated by the 
co-presence of nephrotic syndrome in 30-50% of cases.
12 The hypoalbuminaemia of nephrotic 
syndrome is itself exacerbated by concomitant liver disease. Hypotension can be present not 
only because of a “low-output” state, but also because of associated autonomic neuropathy. 
Involvement of the heart is the commonest cause of death in AL amyloidosis, and a 
major determinant of prognosis; without cardiac involvement, AL amyloidosis has a median 
survival  of  around  4  years
32  but  the  prognosis  among  affected  patients  with  markedly 
elevated BNP and cardiac troponin (Mayo stage III disease)
33 is in the order of 6-8 months.  
 
6.3.2  Hereditary Amyloidoses: 
Mutations in a number of genes, such as TTR, fibrinogen, apolipoprotein A1 and A2 can 
be responsible for hereditary amyloidosis but by far the most common cause is variant ATTR 
amyloidosis, caused by point mutations in the TTR gene leading to neuropathy and often, 
cardiac involvement.  
TTR is synthesised in the liver and a number of point mutations are described (see 
table 1) but the most common is the Val122Ile mutation.
34, 35 In a large autopsy study that 
included individuals with cardiac amyloidosis, the TTR Val122Ile allele was present in 3.9% of 
all African Americans and 23% of African Americans with cardiac amyloidosis. Penetrance of 
the mutation is not truly known and is associated with a late-onset cardiomyopathy that is 
indistinguishable from SSA.  Although the prevalence of disease caused by this mutation is 
unknown, recent evidence suggests it is almost certainly underdiagnosed,
36 since the wall 
thickening is often incorrectly attributed to hypertensive heart disease. The male to female Page 25 of 150 
ratio is around 50:50, in contrast to a slight male predilection in AL amyloid with cardiac 
involvement.
23 
  Over 100 genetic variants of TTR are associated with amyloidosis.  Most present as 
the clinical syndrome of progressive peripheral and autonomic neuropathy. Unlike wild type 
ATTR or variant ATTR Val122Ile, the features of other variant ATTR include, vitreous amyloid 
deposits or rarely deposits in other organs.  Cardiac involvement in variant ATTR varies by 
mutations  and  can  be  the  presenting,  or  indeed  the  only  clinical  feature.
37  For  example, 
cardiac involvement is rare in variant ATTR associated with Val30Met (a common variant in 
Portugal or Sweden), but is almost universal and develops early in individuals with variant 
ATTR due to Thr60Ala mutation (a mutation common in Ireland).  
Mutations in apolipoprotein A1 gene can cause systemic amyloidosis, typically causing 
renal and hepatic involvement  - although cardiac involvement is well recognised.
38  
 
6.3.3  Senile Systemic Amyloidosis:  
Wild type TTR amyloid deposits are found at autopsy in about 25% of individuals older 
than 80 years, but their clinical significance has not been clear
39-41 The epidemiological studies 
assessing the prevalence of wild type TTR deposits, leading to the clinical syndrome of wild 
type ATTR cardiac amyloidosis, remains to be ascertained but is distinct and clearly far rarer.   
Wild Type ATTR is a predominant cardiac disease and the only other significant extracardiac 
feature is a history of carpal tunnel syndrome, often preceding heart failure by 3-5 years.
42, 43  
Extracardiac involvement is most unusual.    
Both wild type ATTR as well as ATTR due to Val122Ile  are diseases of the over 60 year 
old age group and are often misdiagnosed as hypertensive heart disease.
14 Wild Type ATTR 
has  a  strong  male  predominance  and the natural  history  remains poorly  understood,  but 
studies  suggest  a  median  survival  of  about  6-7  years  from  presentation.
39,  40  The  true 
incidence of wild type ATTR is probably underestimated
36 and recent developments in CMR, 
which have greatly improved detection of cardiac amyloid during life, suggest that wild type 
ATTR is more common than previously thought – it accounted for 0.5% of all patients seen at 
the UK amyloidosis centre until 2001 but now accounts of 7% of 1100 cases with amyloidosis 
seen since end of 2009.
44 This observation is also in part explained by the ageing population.  Page 26 of 150 
There appears to be an association between wild type ATTR and history of myocardial 
infarction (MI), G/G (Val/Val) exon 24 polymorphism in the alpha2-macroglobulin (alpha2M), 
and the H2 haplotype of the tau gene;
45 the association of tau with Alzheimer’s disease raises 
interesting  questions  as  both  are  amyloid-associated  diseases  of  ageing.    Whilst  the 
echocardiographic manifestations of cardiac ATTR may be indistinguishable from advanced AL 
amyloidosis, patients with the former typically have fewer symptoms and better survival.
46   
 
6.3.4  Other types of cardiac amyloidosis: 
Localised  atrial  amyloid  deposits  derived  from  atrial  natriuretic  peptide  (ANP),  are 
associated  with  AF,  notably  post  operatively
14,  47  and  become  ubiquitous  with  age,  being 
present at autopsy in 80% of over 70s.
48,  49 The significance and causality of ANP amyloid 
deposits remain unknown.  Amyloid of as yet unknown fibril type is also common in explanted 
cardiac valves.
50, 51  Systemic AA amyloidosis complicating chronic inflammatory diseases, in 
which the amyloid fibrils are derived from the acute-phase reactant, serum amyloid A (SAA) 
protein, involves the heart in about 2% of cases with systemic AA amyloidosis.  Incidence of 
AA amyloidosis is generally in decline, likely reflecting better treatment for rheumatological 
disorders with biological agents.   
 
6.4  DIAGNOSIS AND EVALUATION OF CARDIAC AMYLOIDOSIS:  
6.4.1  Electrocardiography (ECG):  
Low QRS voltages (all limb leads <5 mm in height) with poor R wave progression in the 
chest  leads  (pseudoinfarction  pattern)  occur  in  up  to  50%  of  patients  with  cardiac  AL 
amyloidosis.
52  The  combination  of  low  ECG  voltage  with  concentrically  increased  wall 
thickness is highly suspicious for cardiac amyloidosis (see figure 2), but voltage criteria for left 
ventricular hypertrophy (LVH) can nevertheless sometimes occur.
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Figure 2: ECG of a patient with Cardiac AL Amyloidosis showing small QRS voltages (defined as ≤6mm 
height), predominantly in the limb leads and pseudoinfarction pattern in the anterior leads. 
 
A recent, small evaluation of ECGs in cardiac AL amyloidosis
52 supported the findings of 
the largest reported ECG series of 127 patients with AL amyloidosis and biopsy-proven cardiac 
involvement seen at the Mayo Clinic. The 2 most common abnormalities were low voltage 
(particularly in the limb leads) and a pseudoinfarction pattern, which were seen in 45-50% of 
cases. The mechanisms, however, are poorly understood.  
Other  findings  include  first  degree  atrioventricular  (AV)  block  (21%),  nonspecific 
intraventricular  conduction  delay  (16%),  second  or  third  degree  AV  block  (3%),  AF/flutter 
(20%), and ventricular tachycardia (VT) (5%).
53 Left (LBBB) and right bundle branch block can 
also  occur.
23  ECG  patterns  can  provide  clues  to  differentiate  between  AL  and  ATTR 
amyloidosis: LBBB is seen in 40% of patients with wild type ATTR but is rare in AL (4%), while 
typical low QRS voltages are seen in 40%  wild type ATTR vs 60% AL.
55   
There  has  been  little  recent  study  of  ECG  correlation  with  cardiac  biomarkers, 
treatment toxicity and mortality.  Progressive ECG changes may be useful in assessing silent 
cardiac progression.
56 Changes in ECG abnormalities after treatment in AL amyloidosis remain 
poorly studied, but can occur – more often, little improvement is seen. Holter ECG monitoring 
identifies asymptomatic arrhythmias in >75% of cardiac AL patients (mainly supraventricular 
tachyarrhythmias and some non-sustained VT).
57   
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6.4.2  Echocardiography: 
All patients with suspected amyloidosis should undergo echocardiography.  Findings 
are characteristic in advanced disease, but harder to elicit earlier on, and have prognostic as 
well  as  diagnostic  significance.
58-60  Typical  findings  include  concentric  LVH  with  right 
ventricular (RV) involvement, poor biventricular long axis function with (near) normal ejection 
fraction (EF)
61, 62 and valvular thickening (particularly in wild type or variant ATTR).
55  Diastolic 
dysfunction  is  the  earliest  echocardiographic  abnormality  and  may  occur  before  cardiac 
symptoms  develop.
63,  64  As  with  all  investigations,  echocardiography  must  be  interpreted 
within  the  clinical  context;  a  speckled  or  granular  myocardial  appearance,  although 
characteristic of amyloid, is an inexact finding which is dependent on machine gain settings.  
Biatrial dilatation in presence of biventricular, valvular and interatrial septal thickening 
63 are 
useful clues to the diagnosis.   
Advanced  echocardiographic  techniques  are  beginning  to  reveal  more  about  the 
underlying pathology and functional abnormalities, such as the twisting and untwisting cardiac 
motion  that  may  be  augmented  through  compensatory  mechanisms  before  reversing  to 
impairment later in the course of the disease.
65, 66 Strain and strain rate imaging, derived from 
speckle tracking (see figure 3), may help differentiate cardiac amyloidosis from hypertrophic 
cardiomyopathy.
67, 68  
 
Figure 3: Transthoracic echocardiogram with speckle tracking:. The red and yellow lines represent 
longitudinal motion in the basal segments while the purple and green lines represent apical motion. 
This shows loss of longitudinal ventricular contraction at the base compared to apex. 
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Typically, there is much greater restriction of basal compared to apical movement.  
Mean LV basal strain is an independent predictor of both cardiac and overall deaths. Contrast 
echocardiography using transpulmonary bubble contrast can show microvascular dysfunction 
in  AL  amyloidosis.
69    Although  transoesophageal  echo  may  help  detect  atrial  appendage 
thrombus in a third of cases, of AL amyloid – translation of this into routine clinical practice for 
this frail and unwell patient population needs further study.
63, 70 
 
6.4.3  Cardiac Biomarkers 
Measurements of BNP, its more stable N-terminal fragment (NT-proBNP), and cardiac 
troponins are extremely informative in AL amyloidosis, which is the only type in which they 
have  been  systematically  studied  to  date.  Their  value  in  ATTR  amyloidosis  is  yet  to  be 
determined. BNP/NT-proBNP are cleared by the kidneys (BNP also partially cleared by the 
liver), confounding evaluation of patients with kidney involvement. Elevated NT-proBNP levels 
in  systemic  AL  amyloidosis  are  a  sensitive  marker  of  cardiac  involvement,  with  a  cut-off 
>152pmol/L being associated with higher mortality (72% vs 7.6% per year).
71 Abnormal NT-
proBNP  is  predictive  of  clinically  significant  cardiac  involvement  developing  in  future.
72  
BNP/NT-proBNP, in general, reflects high filling pressures, but amyloid deposits may have a 
local effect – BNP granules are found in higher quantities in myocytes adjacent to amyloid 
deposits.
73  
Increased  troponin  concentrations  are  a  marker  of  poor  prognosis
74  but  the 
mechanism remains unclear. In a study of 261 patients with newly diagnosed AL amyloidosis, 
median survival for patients with or without detectable levels of Troponin T was 6 months and 
22 months, respectively.
74 Indeed more recently, high-sensitivity Troponin T has been shown 
to  correlate  with  morbidity  and  mortality  after  patients  with  renal  impairment  were 
excluded.
75 High-sensitivity Troponin is abnormal in more than 90% of cardiac AL patients,
76 
and the combination of BNP/NT-proBNP plus troponin measurements are used to stage and 
risk-stratify patients with AL amyloidosis at diagnosis.
33, 77  
Interestingly,  the  concentration  of  BNP/NT-proBNP  in  AL  amyloidosis  may  fall 
dramatically within weeks following chemotherapy that substantially reduces the production 
of  amyloidogenic  light  chains.
78  The  basis  for  this  very  rapid  phenomenon,  which  is  not Page 30 of 150 
mirrored by changes on echocardiography or CMR remains uncertain, but a substantial fall is 
associated with improved outcomes.
79 An early transient increase in BNP/NT-proBNP may 
occur  after  treatment  with  the  immunomodulatory  drugs  thalidomide  and  lenalidomide, 
which  are  frequently  used  in  the  management  of  AL  amyloidosis  (see  later),  but  the 
significance and cause is unclear.
80, 81   
 
6.4.4  Radionuclide Imaging: 
Serum amyloid P component (SAP) scintigraphy uses purified human SAP radiolabelled 
with 
123I, which is injected into patients. The tracer localises to target organs rich in amyloid 
and an image captured with a gamma camera. SAP scans enable visceral amyloid deposits, 
including those in the liver, kidneys, spleen, adrenal glands and bones to be imaged serially in 
a specific and qualitative manner.
82 It does not adequately image the moving heart, in part 
because  the  high  atomic  mass  of  SAP  (125kDa)  prevents  movement  across  myocardial 
capillary endothelium and thus has no role in assessing cardiac amyloidosis. SAP scans are 
described further and illustrated in section 6.5 “Liver and Spleen,” later in this chapter.  
Numerous case reports over the past 30 years have indicated that various commonly 
used  diphosphonate  bone  seeking  radionuclide  tracers  occasionally  localise  to  cardiac 
amyloid,  and this  approach  has  lately  been  investigated  systematically.    It  transpires  that 
technetium-labelled  3,3-diphosphono-1,2-propanodicarboxylic  acid  bone  scanning  agent 
(
99mTc-DPD), a particular tracer that has been little used of late for bone scintigraphy, appears 
to localise to cardiac amyloid deposits very sensitively, especially in patients with ATTR type 
(see figure 4), where it has become the gold standard imaging test for cardiac ATTR amyloid.  
Indeed, asymptomatic cardiac ATTR deposits can be identified through 
99mTc-DPD scintigraphy 
at an early stage when echocardiography, serum cardiac biomarkers and perhaps even CMR 
remain normal.
 82   
By contrast, uptake of 
99mTc-DPD occurs in about one third of patients with cardiac AL 
amyloidosis, and 
99mTc-DPD-SPECT-CT can help to distinguish the two types.
83  The sensitivity 
of DPD scintigraphy for detecting cardiac amyloidosis of ATTR type would appear to have 
considerable potential for diagnosis and screening.
84  Early work using N-[methyl-(11)C]2-(4’-Page 31 of 150 
methylamino-phenyl)-6-hydroxybenzothiazole ((11)C-PIB) PET imaging for cardiac amyloidosis 
is promising.
85  
 
 
Figure 4: A positive 
99mTc-DPD scan for ATTR cardiac amyloid (left), showing uptake in the heart (arrow) 
and reduced bone uptake. The right hand panel showed a fused CT/SPECT image showing myocardial 
uptake with greater uptake in the septum.  
 
  In reality, because of the much lower sensitivity of DPD scintigraphy in AL compared 
with  ATTR  amyloidosis,  a  multimodality  imaging  approach  is  adopted  using  radionuclide 
scintigraphy as described above, along with cardiac MRI as described below. 
 
6.4.5  Cardiac MRI: 
CMR provides functional and morphological information on cardiac amyloid in a similar 
way to echocardiography, though the latter is superior for evaluating and quantifying diastolic 
abnormalities.  An advantage of CMR is in myocardial tissue characterisation.  Amyloidotic 
myocardium reveals subtle (but see later with the new methods) pre-contrast abnormalities 
(T1, T2)
86,  87 but extravascular contrast agents based on chelated gadolinium provided key 
information.  The  appearance  (see  figure  5)  of  global,  subendocardial  LGE,  is  highly 
characteristic of cardiac amyloid
88, 89 and correlates with prognosis,
90, 91 although other LGE 
patterns are also recognised (see figure 6). These factors are explored in more detail later in 
this  thesis.  CMR  is  especially  useful  in  patients  with  other  causes  of  LVH,  since  it  can 
differentiate  amyloidosis  from  hypertension,  which  may  not  be  possible  by  routine 
echocardiography.    Page 32 of 150 
 
Figure 5: CMR with the classic amyloid global, subendocardial late gadolinium enhancement pattern in 
the left ventricle with blood and mid-/epi-myocardium nulling together. 
 
 
Figure 6: LGE patterns: (A) Characteristic global, subendocardial; (B) patchy; (C) extensive and (D) LGE 
in a patient without hypertrophy (maximum wall thickness in this individual was 10mm) 
 
Difficulties are however often encountered, for example arrhythmias, particularly AF 
and  ectopic  beats,  degrade  image  quality  during  CMR,  and  increasing  experience  of  the 
technique in clinical practice has shown that the pattern of LGE can be atypical and patchy, 
especially in early disease.
92 LGE imaging in amyloidosis is inherently challenging since amyloid 
infiltration  within  the  interstitium  of  the  heart  reduces  the  differences  in  contrast  signal 
between blood and myocardium such that the two compartments may null together or even 
be reversed and effusions may cause considerable ghosting artefact, although these both can 
be a strong clue to the underlying diagnosis (see figure 7).
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Figure 7: Sequential static images from a CMR TI scout sequence after gadolinium administration.  As 
the inversion time (TI) increases, myocardium nulls first (arrow in image 3), followed by blood 
afterwards (arrow in image 6), implying that there is more gadolinium contrast in the myocardium 
than blood 
 
6.4.6  Endomyocardial biopsy: 
Endomyocardial biopsy has been considered to be the gold standard for demonstrating 
cardiac amyloid deposition.
95 Although cardiac involvement can reasonably be inferred in a 
patient with proven systemic amyloidosis through a combination of clinical features, ECG, 
echocardiography and biomarkers etc., endomyocardial biopsy is required when suspected 
cardiac amyloidosis is an isolated feature and/or when identification of the cardiac amyloid 
fibril type cannot be defined by other means. In practice, endomyocardial biopsies are most 
commonly  required  to  differentiate  between  AL  and  ATTR  in  older  patients,  some  5%  of 
whom have a monoclonal gammopathy of undetermined significance (MGUS),
96 and should 
be  considered  in  patients  with  LV  thickening  by  echocardiography  where  hypertension, 
valvular disease and a family history of HCM have been excluded, particularly if the patient is 
young.   
Complications such as perforation remain a small but real risk and may not be well 
tolerated in restrictive cardiomyopathy.
97,  98 The presence of amyloid deposition should be 
confirmed by Congo red staining, and immunohistochemistry can usefully identify fibril type in 
about 60-70% cases. Electron microscopy to confirm or refute the presence of amyloid fibrils 
has  an  occasional  role  when  Congo  red  stains  fail  to  produce  definitive  results.
99,  100  
Proteomic typing of amyloid by mass spectrometry using tiny samples obtained through laser Page 34 of 150 
capture micro-dissection of tissue sections usually provides definitive results,
101 and is critical 
when immunohistochemistry has not done so.   
 
6.5  LIVER AND SPLEEN: 
  The liver is affected in around 25-30% with Systemic AL Amyloidosis. It presents either 
as  hepatomegaly  or  as  previously  undetected  liver  enzyme  derangement.
31  Rarely,  it  can 
present with life threatening hepatic rupture,
102 which is also seen in some other hereditary, 
non-TTR amyloid types.
103  
SAP scintigraphy is the gold standard for assessing disease burden within the liver. As 
mentioned  earlier,  its  high  atomic  mass  of  125kDa  favours  evaluation  of  tissues  with  a 
fenestrated  endothelium,  such  as  the  liver  and  spleen.  A  qualitative  assessment  is  made 
ranging from the “congested” appearance seen in ATTR type amyloid, to the small, moderate 
and large loads seen in AL and some other hereditary, non-ATTR amyloids (see figure 8). 
 
Figure 8: SAP scans showing (A) Large amyloid load in liver and spleen in a patient with AL Amyloidosis; 
(B) Congested liver and spleen in a patient with TTR amyloid 
 
Splenic amyloid is seldom of clinical significance and is most commonly involved in AA 
Amyloidosis, but some cases of AL Amyloid also show uptake on SAP scintigraphy (see figure 
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Figure 9: SAP scan showing moderate load in the spleen and the right adrenal gland (arrow) in a 
patient with AA Amyloidosis 
 
6.6  SKELETAL MUSCLE: 
Skeletal muscle amyloidosis is rare and little is known about it. It has been described in 
hereditary Apo A2
104 and senile amyloidosis
105 in mice. Primary (AL) Amyloidosis can however 
also present with myopathy (e.g. dropped head syndrome)
106 and there are a number of case 
reports of patients with myeloma / lymphoma who have amyloid deposits in skeletal muscle 
histologically, with confirmed myopathic changes on EMG.
107-109 There is no good non-invasive 
imaging technique to diagnose this condition. CT scanning can reveal infiltrative changes but 
muscle biopsy remains the diagnostic gold standard.  
 
6.7  PROGNOSIS: 
In  the  absence  of  treatment,  the  natural  history  of  AL  amyloidosis  is  rapidly 
progressive, with death occurring within 2 years in about 80% of patients;
14 it is much worse 
with  cardiac  involvement  and  heart  failure.  In  a  study  of  18  patients  with  amyloid  heart 
involvement due to SSA, the median survival was 60 months; over the same period, patients 
with  AL  amyloid  heart  disease  at  the  same  institution  had  a  median  survival  of  only  5.4 
months.
40 Despite thicker walls and an older age, the senile amyloid patients had less severe 
heart failure and a much longer median survival (75 vs 11 months). Similar results have been 
recently reported in a large series comparing different forms of amyloid cardiomyopathy.
55  
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5.8  TREATMENT: 
Cardiac  amyloidosis  in  general  has  a  poor  prognosis,  but  this  differs  according  to 
amyloid type, and availability and response to therapy.  Treatment may be “amyloid-specific” 
or “non amyloid-specific” as detailed below: 
6.8.1  Non Amyloid Specific: 
6.8.1.1  Heart Failure Therapy: 
Standard heart failure therapy may be of limited benefit or even detrimental in cardiac 
amyloidosis.  There is scanty evidence for the use (or not) of ACE-i, ARBs and β-blockers.  
These may be poorly tolerated, worsen postural hypotension or renal function (ACE/ARBs) 
Restrictive cardiomyopathy leads to a heart-rate dependent cardiac output in some cases and 
such patients may find difficulty in tolerating beta-blockers.  Digitalis and calcium channel 
blockers  may  be  selectively  concentrated  in  amyloidotic  tissue  and  are  relatively 
contraindicated on grounds of increased toxicity
110-112 especially the latter, which can lead to 
rapid worsening.  Careful monitoring is needed to avoid significant drug interactions e.g. β-
blockers with thalidomide used in chemotherapy of AL amyloidosis causing bradycardia.
113   
Maintenance of adequate filling pressures is vital due to the restrictive physiology; 
balancing peripheral oedema and renal impairment with salt/water restriction and judicious 
use of diuretics is also important.  Patient education and participation, ideally with backup 
from heart-failure teams, is critical to successful management.  Contrary to standard heart 
failure  management,  maintenance  of  adequate  blood  pressure  with  an  α-agonist  like 
midodrine may permit higher doses of loop diuretics especially in patients with autonomic 
neuropathy.
114  
 
6.8.1.2  Device therapy: 
Pacemakers or implantable cardioverter-defibrillators (ICDs) may not prevent sudden 
cardiac death, since this is thought to often be due to electromechanical dissociation.
115 In the 
absence  of  evidence,  pacing  indications  remain  within  current  standard  guidelines.    High 
defibrillator  thresholds  may  be  encountered  and  the  benefits  of  such  devices  remain 
uncertain.
115 
116,  117 Biventricular pacing appears to play little role – but may be the ideal Page 37 of 150 
pacing option of choice to avoid decompensation of the stiffened ventricle as a result of 
induced dyssynchrony from RV pacing. 
118   
6.8.1.3  Cardiac transplantation in amyloidosis: 
Cardiac transplantation has played a disappointingly small role, due to the multisystem 
nature  of  amyloidosis,  advanced  age,  treatment  related  complications,  and  rapid  disease 
progression.    Furthermore,  patients  with  AL  amyloidosis  must  be  deemed  likely  to  be 
sufficiently fit to undergo chemotherapy afterwards, to address the underlying bone marrow 
disorder.  As a result, only a few dozen cardiac transplants have ever been performed for 
amyloidosis.  However, the long-term outcome can be good in highly-selected patients with 
AL amyloidosis.
119  Cardiac transplantation followed by successful peripheral blood autologous 
stem cell transplantation (ASCT) was associated with better survival in selected patients as 
reported
120 from most major amyloidosis units in the UK,
119 France,
121 Germany
122 and the 
USA.
123   
A suitable patient with AL amyloidosis is likely to be young (<60 yrs), have isolated 
Mayo stage III cardiac amyloidosis, NYHA III or IV symptoms after adequate diuretics, good 
renal/liver function, no significant autonomic neuropathy, low level bone marrow plasma-
cytosis and be eligible  for ASCT after the heart transplant.  Even in such patients, outcomes 
are probably inferior to other indications.
124 For variant ATTR, combined cardiac and liver 
transplantation has been performed in a few dozen cases throughout the world.
119, 120, 125, 126  
Although most patients with wild type ATTR are too elderly for cardiac transplantation, the 
absence of extra-cardiac involvement renders younger patients with wild type ATTR excellent 
candidates.    The  two  patients  with  wild  type  ATTR  who  presented  to  the  UK  national 
amyloidosis centre before age 60, survived 10 and 20 years respectively following cardiac 
transplantation (unpublished data).  
 
6.8.2  Amyloid Specific: 
6.8.2.1  Reducing amyloid fibril precursor protein production: 
  Treatment of amyloidosis is currently based on the concept of reducing the supply 
of  the  respective  amyloid  fibril  precursor  protein.    In  AL  amyloidosis,  therapy  is  directed 
towards the clonal plasma cells using either cyclical combination chemotherapy or high dose Page 38 of 150 
therapy with ASCT.  Most chemotherapy regimes in AL amyloidosis comprise dexamethasone 
combined with an alkylator (oral melphalan or others).   
  Addition  of  thalidomide,  for  example  in  the  risk-adapted  cyclophosphamide, 
thalidomide and dexamethasone (CTD) regime used widely in the UK, improves response rates 
but probably at cost of greater toxicity.
127 Dexamethasone, although a very useful agent in all 
patients with AL amyloidosis including those with cardiac involvement, has to be used with 
great caution  in patients with cardiac amyloidosis due to  a high risk of fluid overload in the 
absence of adequate and rapid changes to diuretic therapy.  Close coordination between the 
treating haematology and cardiology teams is critical to steer the patient successfully through 
the  treatment  course.
128  In  a  study  of  75  AL  patients,  CTD  (and  attenuated  dose  CTD) 
produced a complete response (CR) in 21%. Estimated 3-year survivals for those achieving a 
CR, partial response (PR), or no response were 100%, 82%, and 0%, respectively  (median 
survival 17 months).   
  High-dose  melphalan  followed  by  ASCT  provides  a  more  durable  haematological 
response. In the largest published series of melphalan-primed ASCT (n=701), 312 AL patients 
were  deemed  eligible  for  high-dose  chemotherapy,  and  the  median  survival  of  treated 
patients was 4.6 years. A CR was achieved in 40%, although the mortality rate in the first 100 
days was 13%. Survival was poorer amongst patients with cardiac amyloidosis compared to 
those who had no evidence of heart involvement.
129 Although it has been argued that ASCT is 
the  best  treatment  for  suitable  patients,
130-132  its  role  in  the  era  of  more  novel  agents 
(discussed below), is less certain.   
  The newer treatment options include bortezomib (a proteosome inhibitor)
133 and 
the newer immune-modulatory drugs, such as lenalidomide and pomalidomide. Bortezomib 
combinations  appear to  be  especially  efficient in  amyloidosis  with  high  rates  of  near  CRs 
which  appear  to  translate  into  early  cardiac  responses.
134-136  Phase  II  (bortezomib  in 
combination with cyclophosphamide or doxorubicin) and phase III (bortezomib, melphalan 
and dexamethasone compared to melphalan and dexamethasone as front line treatment) 
trials are underway.   
AA amyloidosis is the only other type of amyloidosis in which production of the fibril 
precursor  protein  can  be  effectively  suppressed  by  currently  available  therapies.    Anti-
inflammatory therapies, for example anti-TNF agents in rheumatoid arthritis, can substantially Page 39 of 150 
suppress serum amyloid A protein production, but very little experience has been obtained 
regarding cardiac involvement which is very rare in this particular type of amyloidosis. 
ATTR is produced almost exclusively in the liver. Liver transplantation has been used as 
a treatment for variant ATTR for 20 years, to remove genetically variant TTR from the plasma.  
Although this is a successful approach in ATTR Val30Met, it has had disappointing results in 
patients with other ATTR variants which often involve the heart.  The procedure commonly 
results in progressive cardiac amyloidosis through on-going accumulation of wild-type TTR on 
the  existing  template  of  variant  TTR  amyloid.
137  The  role  of  liver  transplantation  in  non-
Val30Met  associated  hereditary  TTR  amyloidosis  thus  remains  very  uncertain.  Exercise 
training post surgery can be helpful however.
138  
ATTR amyloidosis has lately become a focus for novel drug developments aimed at 
reducing production of TTR through silencing RNA and antisense oligonucleotide therapies.  
ALN-TTR01, a systemically delivered silencing RNA therapeutic
139 is already in phase I clinical 
trial.   
 
6.8.2.2  Inhibition of amyloid formation: 
Amyloid  fibril  formation  involves  massive  conformational  transformation  of  the 
respective precursor protein into a completely different form with a predominantly β-pleated 
sheet structure.  The hypothesis that this conversion might be inhibited by stabilising the fibril 
precursor  protein  through  specific  binding  to  a  pharmaceutical  product  has  lately  been 
explored in ATTR amyloidosis.  A key step in TTR amyloid fibril formation is the dissociation of 
the normal TTR tetramer into a monomeric species that can auto-aggregate into a misfolded 
form.    In  vitro  studies  identified  that  diflunisal,  a  now  little  used  non-steroidal  anti-
inflammatory analgesic, is bound by TTR in plasma, and that this enhances the stability of the 
normal soluble structure of the protein.
140, 141  Studies of diflunisal in ATTR are in progress.  
Tafamidis is a new compound without anti-inflammatory analgesic properties that has 
a similar mechanism of action.  Tafamidis has just been licensed for neuropathic ATTR but its 
role  in  cardiac  amyloidosis  remains  uncertain  –  clinical  trial  results  are  eagerly  awaited.   
Higher affinity ‘superstabilizers’ are also in development.
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Eprodisate is a negatively-charged, sulphonated molecule with similarities to heparin 
sulphate, which is being pursued as a treatment for AA amyloidosis.  Eprodisate is thought to 
inhibit the pro-amyloidogenic interactions of GAGS with SAA during fibril formation in AA 
amyloidosis.    A  phase  III  trial  showed  benefits  in  terms  of  progression  of  AA  amyloid 
associated renal dysfunction
143 and further studies are currently being conducted.   
 
6.8.2.3  Targeting Amyloid Deposits by Immunotherapy: 
Amyloid  deposits  are  remarkably  stable,  but  the  body  evidently  has  some  limited 
capacity to remove them.  Following treatment that prevents the production of new amyloid, 
e.g.  successful  chemotherapy  in  AL  type,  amyloid  deposits  are  gradually  mobilised  in  the 
majority of patients, though at different rates in different organs and between individuals.  
Unfortunately  clearance  of  amyloid  is  especially  slow  in the  heart,  and  echocardiographic 
evidence of improvement is rare, even over several years.  
The challenge of developing a therapeutic monoclonal antibody that is reactive with all 
types of amyloidosis is currently being addressed by targeting SAP, since this is a universal 
constituent of all amyloid deposits and an excellent immunogen. Anti-SAP antibody treatment 
is clinically feasible because circulating human SAP can be depleted in patients by the bis-d-
proline compound CPHPC, thereby enabling injected anti-SAP antibodies to reach residual SAP 
in the amyloid deposits (see figure 10 on the next page).
3  The unprecedented capacity of this 
novel combined therapy to eliminate amyloid deposits in mice is encouraging and should be 
applicable to all forms of human systemic and local amyloidosis; trials are currently underway.  Page 41 of 150 
 
Figure 10: Showing (A) cross-linking of SAP by the R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl] 
pyrrolidine-2-carboxylic acid (CPHPC) molecule; (B) Circulating SAP in a patient with amyloidosis, 
showing the normal level of “coating” of amyloidotic organs by SAP and baseline low-level 
sequestration of circulating SAP by the liver; (C) Addition of CPHPC causing cross-linking of SAP in the 
blood and subsequent high level excretion of SAP from blood by the liver; (D) Addition of the anti-SAP 
antibody causing removal of SAP coating from amyloidotic organs, allowing immune system to destroy 
the amyloid in the target organ. Picture courtesy of Duncan Richards, GSK.  
 
6.9  MEASURING INTERSTITIAL EXPANSION USING MRI: 
6.9.1  MRI General Physics: 
The majority of protons in the body align in the direction of the magnetic field B0 when 
placed in the MRI scanner, as this is the lower energy state. A radiofrequency (RF) impulse at 
the Larmor frequency induces a higher energy state within the proton, causing it to spiral 
away from the B0 alignment to an angle (flip angle) proportionate to the RF pulse. When the 
RF pulse stops, the proton slowly relaxes and energy is dissipated to the surrounding nuclei; 
this corresponds with the return of longitudinal magnetisation to the original B0 alignment as 
calculated by 1 – e
-t/T1. The time constant of this exponential is known as the T1 relaxation 
time and represents the time taken for 63% of longitudinal magnetisation to recover after the 
RF impulse (see figure 11) Page 42 of 150 
 
Figure 11: Magnetisation recovery curve plotted against time demonstrating T1 for myocardium.  
   
T1 is therefore dependent on magnetic field strength. All tissues have an intrinsic T1 
which is a composite signal representing cells and the interstitium. Any change in cell size or 
number will alter the T1. Similarly, any change in the interstitium such as scarring from MI or 
infiltration by amyloid will also change the T1 from normal. In general, the higher the water 
content, the higher the T1. The T1 of normal myocardium is approximately 960 ± 30ms. A high 
or low myocardial T1 can therefore give tissue characterisation and allow some inference as to 
the cause of the abnormal areas of myocardium in question. For example, the T1 varies widely 
from  as  low  as  300-400ms  in  iron-loaded  hearts  to  almost  2000ms  in  oedematous 
myocardium as seen in myocarditis.  
T1  can  be  significantly  lowered  by  administration  of  Gadolinium.  There  are  many 
preparations, though cyclic, ionic compounds such as Gadoterate Meglumine (Dotarem) are 
thought  to  be  the  safest  in  terms  of  the  lowest  risk  of  nephrogenic  systemic  fibrosis. 
Gadolinium  is  a  purely  extracellular  agent  and  produces  a  local  environment  in  the 
interstitium that allows protons to relax by a factor of x10
6 faster than normal. In areas of 
gross  interstitial  expansion  due  to  amyloid,  gadolinium  concentration  is  proportionately 
higher in these areas and causes the T1 in these areas to drop lower than compared to the 
surrounding or adjacent (normal) tissue (see figure 12), thus producing the contrast between 
black and white in the late gadolinium enhancement pictures shown in figures 6 and 7 earlier. 
This  property  of  gadolinium  is  also  the  crux  of  the  Equilibrium-CMR  technique  described 
shortly in section 6.10. 
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Figure 12: Graph showing change in concentration of gadolinium with time after IV bolus. Blue line 
shows concentrations in the interstitium of normal myocardium and the red line in abnormal 
(infarcted) myocardium. The difference in concentration at 10-20 mins (marked “contrast”) creates the 
standard LGE image with normal myocardium black and scar appearing as white. Picture courtesy of 
Dr. Daniel Sado, The Heart Hospital. 
 
6.9.2  T1 Mapping: 
A number of techniques are currently in widespread use in the CMR community to 
measure T1 values of tissues. The earliest method was using a Look Locker (TI scout) sequence 
prior to the administration of gadolinium contrast (see figure 13), which took multiple images 
throughout several cardiac cycles after an RF pulse. From these, a region of interest  (ROI) 
could be drawn and the signal intensities plotted against time on a recovery curve similar to 
figure 11 to determine the T1. This method had the disadvantage that it required a long 
breath hold from patients and also images were not acquired at the same point in the cardiac 
cycle.  
 
Figure 13: A pre contrast TI scout image showing the different signal intensities of the myocardium at 
increasing time points (100ms to 3882ms) after a RF impulse.   Page 44 of 150 
In 2004, the modified Look Locker T1 mapping (MOLLI)
144 sequence was developed. 
This sends out an RF impulse and reads out at 3 time-points along the T1 recovery curve. A 
further 2 RF impulses are applied to the selected tissue and read outs (3 and 5 respectively) 
along the recovery are taken after each RF impulse. Three recovery curves are then available 
to determine the tissue T1. The result is a pixel by pixel T1 map displayed as a graded colour 
image according to the T1 of each pixel. This is summarised in the schematic in figure 14.  
MOLLI  had  the  advantage  of  being  more  accurate  than  the  Look  Locker  sequence 
because it samples at the sampled at the same point in the cardiac cycle. But the breath hold 
is very long for most patients (around 20 seconds in some instances) and as such, is also more 
susceptible to heart rate changes and ectopics.  
 
Figure 14: Schematic showing 3 RF impulses (boxes) and their subsequent readouts plotted on the 
recovery curve, coloured in green, red and blue respectively.  This produces the colour, pixel by pixel 
T1 map. Courtesy of Dr. Stefan Piechnik, OCMR Unit, Oxford.  
 
Later in 2010, in order to make the MOLLI more clinically applicable, it was shortened 
to  become  the  ShMOLLI.
145  Certain  assumptions  needed  to  be  made  to  achieve  this,  for 
example that the recovery periods after each RF impulse need not be as long as the MOLLI 
such that at heart rates with an R-R interval of approximately 1000msec, even though 3 RF 
impulses were applied, only 1 recovery curve of 5 plots was required to determine the T1 of 
the myocardium; however, if the heart rate was particularly fast or the T1 of the tissue in Page 45 of 150 
question was particularly low, information from the 2
nd and 3
rd recovery curves was then 
taken into consideration. The data obtained from the ShMOLLI experiment then undergoes 
automated mathematical correction and curve fitting performed by the Siemens computer 
which is used to control the scanner. This is used to calculate the T1 of each image pixel in the 
slice selected, which is then assigned a colour according to its value as shown below in figure 
15. 
 
Figure 15: Pre-contrast ShMOLLI image showing (A) Normal myocardium appearing green, and (B) 
Amyloid myocardium appearing thickened with areas of red (high T1 signal) appearing in the otherwise 
green myocardium. 
These assumptions meant the T1 map could now be taken in around 9 seconds. The 
ShMOLLI was also found to be more heart rate independent and T1 independent than the 
MOLLI  as  a  result.  Therefore,  the  pre-contrast  T1  work  presented  in  this  thesis  uses  this 
ShMOLLI technique. 
More recently, the MOLLI has been motion corrected to improve accuracy and newer 
techniques such as the saturation recovery, single-shot acquisition (SASHA) are entering the 
field,
146 but these are not considered in this thesis.  
 
6.10  EQUILIBRIUM CMR (EQ-CMR): 
  Prior to the advent of ShMOLLI, our group in 2009 devised the first method of non-
invasively quantifying in the interstitium of the heart using the technique of EQ-CMR.
147 There 
are 3 principles underlying this technique: (1) Gadolinium infusion to achieve equilibrium; (2) 
T1 measurement before and after gadolinium; (3) Haematocrit result.  
  Because of some of the limitations of T1 mapping at that time, it was felt that the most 
accurate method was T1 measurement using multiple, high resolution, fast, low-angle shot Page 46 of 150 
(FLASH) inversion recovery images of a single, piloted view (usually the 4-chamber view) at 
specific inversion times (TI) ranging from 200ms to 100ms. This was done first of all prior to 
any gadolinium administration and gave the highest resolution images for ROIs to be drawn in 
the heart and blood pool to obtain the mean signal intensity at each TI, as shown in figure 16 
below:  
 
Figure 16: FLASH T1 measurement method for the heart. A 4-chamber slice is shown at different TIs 
with ROIs (blue) drawn in aorta and basal septum. 
 
Mean tissue signal intensities were then plotted against TI. The TI producing the lowest 
signal intensity was identified and the magnitude of the signal intensities plotted to the left of 
this point were made negative. This allowed reconstruction of the full range of the T1 signal 
intensity  inversion  recovery  curve.  A  second-order  polynomial  curve-fitting  technique  was 
used to find the null point (see figure 17). A previously validated algorithm was then used to 
correct for incomplete longitudinal recovery giving a corrected T1.  
 
Figure 17: Graph showing signal intensity plotted against inversion time using a second-order, 
polynomial curve fitting technique to determine the null point and thus the T1 for myocardium.  
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Gadolinium was then administered as an intravenous bolus at a dose of 0.1mmol/kg, 
followed by a primed infusion of gadolinium at a rate of 0.0011mmol/kg/min. The infusion is 
necessary to create true equilibrium and eliminate the effect of gadolinium kinetics on the 
measured T1. If the infusion was not given, the T1 of both blood and myocardium would 
simply drop precipitously after the bolus injection of gadolinium before slowly returning to 
normal  over  the  course  of  an  hour  or  so  (see  figure  18A).  Any  T1  measurement  in  this 
situation  would  be  affected  by  dynamic  movement  of  gadolinium  between  extravascular 
compartments of blood and myocardium.  Additionally, wash in and wash out is slower in 
abnormal myocardium compared to normal myocardium, and there is also the issue of renal 
excretion;  hence,  an  infusion  is  required  to  achieve  true  equilibrium  between  blood  and 
myocardium and thus eliminate any interference in T1 results from gadolinium kinetics (see 
figure 18B).  
 
Figure 18: Graph showing change in inversion time for myocardium and blood, with time after an IV 
gadolinium bolus (time 0) and - (A) No infusion, allowing TI to return to normal over 1 hour and (B) 
Primed gadolinium infusion commencing at T = 15 minutes holding TI stable over the course of the 
infusion. Image courtesy of Dr. Andrew Flett.  
 
Thirty  minutes  after  the  gadolinium  infusion,  equilibrium  is  reached.  The  T1 
measurements  are  again  taken  in  the  manner  described  above.  At  this  stage,  the 
concentration of gadolinium in the interstitium of myocardium and plasma is the same. And as 
the  rate  of  change  of T1  (∆T1)  is  proportional  to  the  concentration  of  gadolinium  in the 
extracellular space (or volume i.e. ECV), then the following equation is true: 
ECV = λ (1-haematocrit) 
where λ = 
              
                   and R1 = 
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The end result is several signal intensity readings for myocardium and blood, before 
and after contrast, at multiple inversion times. These can be plotted on graphs as shown in 
figure 17 earlier, so that the rate of change of T1 for myocardium and blood can be calculated 
(see figure 19 below) and subsequently the ECV calculated.  
 
Figure 19: Graph showing typical changes in signal intensity plotted against inversion time for 
myocardium (blue) and blood (red), both pre- and post-contrast. Image courtesy of Dr. Andrew Flett. 
 
Proof of principle was first demonstrated in 25 patients with severe aortic stenosis (AS) 
undergoing aortic valve replacement (AVR). The ECV was calculated using EQ-CMR and the 
results compared to histology from a septal biopsy performed during the AVR. There was a 
strong correlation of ECV with collagen volume fraction (R
2 0.80, P<0.001), suggesting ECV as 
assessed by EQ-CMR was quantifying diffuse fibrosis in the interstitium accurately (see figure 
20 on the next page).
147 Page 49 of 150 
 
Figure 20: Scatter graph showing linear association of myocardial ECV with collagen volume fraction in 
aortic stenosis. Figure courtesy of Dr. Andrew Flett published in Circulation, 2010.
147 
 
ECV was then assessed in a host of other cardiomyopathies and compared to normals. 
HCM (n=31), MI (n=20), familial dilated cardiomyopathy (DCM, n=31), severe AS (n=66) and 
Anderson Fabry’s disease (AFD, n=17) were compared to 81 healthy volunteers.  Mean ECV 
was statistically significantly higher in HCM (0.29), DCM (0.28) and AS (0.27) compared to 
healthy volunteers (0.25), P<0.001. AFD did not show any rise in ECV as it is a predominantly 
intracellular disease process. Although there is overlap in these “low-ECV” diseases, the ECV 
of the infarct zone of an MI was massively raised at 0.59 compared to normals (P<0.001) in 
keeping with net rise in extracellular space due to myocyte necrosis and scar formation (see 
figure 21).  Page 50 of 150 
 
Figure 21: Graph showing relationship between myocardial ECV and various cardiac diseases as well as 
normal subjects. Figure courtesy of Dr. Daniel Sado published in Heart, 2012.
148  
 
The work above in EQ-CMR led to the hypothesis that: as Amyloidosis is the exemplar 
of an interstitial disease process and as ECV is a purely extracellular measure, the 2 could be 
combined  to  produce  a  powerful  tool  to  not  only  quantify  cardiac  amyloid  burden  more 
accurately, but also become a marker for treatment response and even prognosis. Current 
methods of assessment of cardiac amyloid burden are reliant on surrogate markers of the 
interstitial expansion rather than a true measure of it.  
Wall  thickness  measured  by  echocardiography  is  non-specific  due  to  other  (more 
common) causes of LVH. Low voltage ECGs, as mentioned earlier, is not very sensitive and 
other pathologies e.g. pericardial effusions confound. Serum cardiac biomarkers such as NT-
proBNP and Troponin T are not specific to amyloid and are also affected by renal impairment 
(a common mode of presentation in AL Amyloid) and chemotherapy. Cardiac biopsy is invasive 
and radioisotope scanning is either not useful in AL Amyloid (DPD scan) or simply does not 
image the heart at all (SAP scan).  
Considering  the  poor  prognosis  carried  by  cardiac  AL  amyloidosis,  any  method  of 
accurately  and  non-invasively  quantifying  the  interstitial  expansion  seen  in  cardiac 
amyloidosis, detecting the disease earlier, detecting amyloid regression in cases that improve Page 51 of 150 
and  predicting  survival  optimally  in  order  to  reduce  treatment-related  mortality  as  well 
mortality due to the disease, is most welcome for these patients.  
We hypothesise that T1 mapping and ECV measurement are able to achieve these 
outcomes and these hypotheses are now explored further in this thesis.  
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7.  METHODS 
7.1  ETHICAL APPROVAL: 
Prior to this thesis, Dr. Andrew Flett had obtained ethical approval (ref 07/H0715/101) 
to  study  the  EQ-CMR  technique  in  patients  with  AS  and  HCM  from  the  joint  UCL/UCLH 
committee  on  ethics  of  human  research.  Dr.  Daniel  Sado  then  obtained  2  substantial 
amendments to this which granted permission to recruit and scan healthy volunteers (n=100) 
and patients with cardiac diseases (n unlimited) discussed in this thesis.  
I was jointly appointed across the Heart Hospital and the National Amyloidosis Centre 
(NAC).  I  obtained  3  minor  amendments  to  enable  contact  of  patients  by  phone  for 
recruitment  because  of  the  unavoidable  necessity  to  coincide  CMR  scans  with  patients’ 
existing appointments with the NAC, as many of them come from lengthy distances across the 
UK and Europe. The 2
nd minor amendment was to create a second Patient information leaflet, 
changing it from the general subject of diffuse fibrosis in HCM, DCM and AS to interstitial 
expansion due to amyloid infiltration. The final amendment was to allow ethics to cover the 
National Amyloidosis Centre.  
I subsequently helped with the requirements of setting up CMR as an endpoint for the 
first in man GSK study using my methods as a primary endpoint. 
 
7.2 PATIENTS: 
A total of 179 patients were scanned from the NAC over the course of 2010-2013. 
These patients were usually attending the NAC for a 24 hour period in order to have ECG, 
echo,  SAP  scan  and  a  clinical  consultation.  All  CMR  scans  were  performed  at  the  Heart 
Hospital and it was therefore necessary to transport patients from the NAC to the Heart 
Hospital and back in between their other numerous investigations. This was a limitation of the 
recruitment process.  
Of  these 179  patients, 26  were  follow  up  scans  (2
nd  scans)  and 6  were  interstudy 
reproducibility scans. The remaining 147 scans were of consecutive patients, either with a 
known diagnosis of amyloidosis (i.e. follow up patients) or an unknown diagnosis (i.e. new Page 53 of 150 
referrals), attending the NAC between 2010-2013 with clinical indications for CMR and no 
contraindications to either MRI or gadolinium. Patients in AF on attending the NAC were also 
excluded.  
Of these 147, 8 patients did not have EQ-CMR scans for the following reasons: 
  eGFR <30ml/min (scan done on clinical grounds with patient’s consent to gadolinium) 
(n=2) 
  Poor pre-contrast T1 map (FLASH only patients) (n=2) 
  Severely orthopnoeic (n=2) 
  Patient refusal (n=1) 
  Side effects (nausea & vomiting) on gadolinium infusion, therefore infusion terminated 
(n=1) 
This left 139 patients who had full EQ-CMR; these are categorised as follows: 
  AL      100 
  ATTR    19 
  AA     3 
  Other hereditary  4 
  Localised    2 
  No amyloid  11 
All patients had, as part of their routine clinical work up, tissue biopsy proof of amyloid 
except 2 patients in the AL cohort – 1 who died before a biopsy could be obtained and the 
other had a normal soft tissue biopsy but with a diagnostic SAP scan showing bone marrow 
uptake. Histology was performed with Congo red followed by immunohistochemical staining, 
these results are shown later in this thesis. 
Before  having  their  CMR  scan,  all  patients  were  subgrouped  into  their  pre-test 
probability of having cardiac involvement as follows:
149 
Definite cardiac involvement – any of: 
  Left ventricular wall thickness of ≥12mm by echocardiography in the absence of any other 
known cause  
  RV free wall thickening co-existing with LV thickening by echocardiography in the absence 
of systemic or pulmonary hypertension Page 54 of 150 
Possible cardiac involvement – any of: 
  LV wall thickening by echocardiography in the presence of hypertension 
  RV thickening by echocardiography in the presence of pulmonary hypertension 
  Normal wall thickness by echocardiography with diastolic dysfunction and raised serum 
biomarkers
33  
No suspected involvement 
  Normal wall thickness by echocardiography with normal serum biomarkers 
The majority of chapters in this thesis refer solely to the AL Amyloid cohort. Some chapters 
(e.g. reproducibility, pilot EQ-CMR in ATTR amyloidosis) also include the ATTR cohort.  
 
7.3  HEALTHY VOLUNTEERS: 
Over the course of the 2 year period, healthy volunteers (n=82) were recruited through 
advertising in hospital, University and general practitioner surgeries. All  had no history or 
symptoms  of  cardiovascular  disease  or  diabetes  and  were  asked  to  fill  in  a  health 
questionnaire  on  arrival  for  their  CMR  scan.  No  patient  was  on  cardio-active  medication 
except 4 on statins for primary prevention. These scans were performed and reported by Dr. 
Daniel Sado and Dr. Viviana Maestrini as a comparator group for ECV studies within our group.  
Some  were  scanned  before  we  had  the  ShMOLLI  sequence  available  to  us  and 
therefore only 54 of the 82 healthy volunteers were scanned using the ShMOLLI T1 mapping 
sequence.  
 
7.4  CMR: 
All scans were performed on a 1.5 Tesla Siemens™ Avanto scanner and images always 
acquired during breath-hold at end expiration.  
 
7.4.1  Pilot Images: 
All studies started with single shot pilot images with the following settings: repeat time 
(TR): 3.39ms, echo time (TE): 1.7ms, slice thickness, 5mm, field of view (FOV) 360 x 360mm, 
read matrix 256 and flip angle 60
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7.4.2  Cine Images: 
After piloting, steady state free precession (SSFP) cine imaging was then undertaken, 
firstly in the long axis planes with a short axis cut through the aortic valve. A standard LV short 
axis stack was then acquired using a slice thickness of 7mm with a gap of 3mm. Retrospective 
ECG gating was used with 25 phases. Typical fast imaging with steady state precession (FISP) 
imaging parameters were TE: 1.6ms, TR: 3.2 ms, in plane pixel size 2.3 x 1.4mm, slice thickness 
7mm, flip angle 60. These settings were optimised accordingly if the subject was unable to 
breath-hold, or had an arrhythmia etc.. 
 
7.4.3  Pre Contrast T1 Assessment: 
7.4.3.1  FLASH Heart: 
Next,  pre-contrast  T1  assessment  for  the  heart  was  performed  using  the  method 
described in section 6.10 which is a multi–breath-hold, spoiled gradient echo, FLASH inversion 
recovery sequence with the following parameters: slice thickness 8mm, flip angle=21°, FOV 
400x260mm and a TR and TE set according to the heart rate to avoid misgating. Images were 
taken at increasing TIs of 140 ms, then 200 to 1000 ms in 100ms increments subsequently 
corrected for heart rate. 
A pre-saturation band was placed across the cerebrospinal fluid (CSF) to avoid ghosting 
onto the ventricular septum in the 4-chamber view, allowing a clean ROI to be drawn on the 
septum. All ROIs were drawn in the 4-chamber view as shown in figure 16 (on page 46) taking 
care to avoid the extremities of the blood:endocardial boundary. The signal intensity at each 
TI is then plotted on a pre-designed MS Excel® graph and the T1 calculated, as described in 
section 6.10. 
For  intrastudy  reproducibility,  scans  were  firstly  analysed  by  myself  before  being 
anonymised and randomised by Dr. Viviana Maestrini and then subsequently re-analysed by 
myself  within  24  hours;  ECV  results  were  collected  by  Dr.  Maestrini.  For  interobserver 
reproducibility, scans analysed and reported by myself were anonymised; the second reporter 
was  Dr.  Maestrini  and  ECV  results  were  collated  by  me  within  7  days.  For  interstudy 
reproducibility,  scans  were  performed  no  more  than  14  days  apart.  These  scans  were 
anonymised and both reported by myself with ECV results collated by Dr. Maestrini.  Page 56 of 150 
7.4.3.2  FLASH Liver, Spleen and Skeletal Muscle: 
For the liver, spleen and skeletal muscle, axial, sagittal and coronal plane localisers 
were used to plan an axial slice through the upper abdomen to include the greatest area of 
liver and spleen. Pre-contrast FLASH images were acquired at this location (as for the heart) 
for T1 measurement with inversion times increasing from 140 to 200ms and then to 1000ms 
in 100ms increments.  
In the liver, a single, large, peripherally-based, wedge-shaped polygonal ROI was drawn 
in liver segment 6 and 7 so as to include the maximum area of liver tissue, but avoid visible 
hepatic and portal veins. These were non-gated acquisitions with a standard TR of 2000msec 
every time. A single image is shown as an example in figure 22.  
Elliptical ROIs were also drawn in the spleen and paravertebral muscle to include the 
maximum area of tissue and avoid adjacent vessels and fat. A circular ROI was drawn in the 
abdominal aorta so as to include the greatest area of lumen, but not include aortic wall – 
frequently thickened by atheroma (see figure 22). 
 
Figure 22: Pre contrast axial MR image (inversion time, 800 msec) shows sample ROIs drawn within the 
abdominal aorta, spleen, liver, and paravertebral muscle. 
 
The 4 ROIs were then copied to the EQ phase FLASH images and mean signal intensity 
within  each  tissue  at  each  TI  recorded  before  being  plotted  on  the  MS  Excel®  graph  as 
described above in section 6.10. Interstudy variability was tested for the liver and spleen as 
described on page 55 using Pearson’s correlation coefficient and Bland-Altman analysis.  
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7.4.3.3  ShMOLLI Heart, Liver and Spleen: 
In  some  AL  amyloid  patients  (n=73)  and  healthy  volunteers  (n=54),  ShMOLLI  T1 
mapping  of  the  heart,  liver  and  spleen  were  also  performed  in  addition  to  FLASH  T1 
measurement. For the ShMOLLI mapping, typical setting were: FOV 340 x 340mm, FOV phase 
69.8%, flip angle 35
o, TR 1095msec, TE 1.05msec, slice thickness 8mm, 107 phase encoding 
steps, interpolated voxel size=0.9x0.9x8mm, base resolution 193 and phase resolution 100. 
Acquisition time was 206msec for a single image with a cardiac (trigger) delay time (TD) of 
500ms; where necessary, to avoid misgating, the TD was decreased by 100ms for every 10 
beats per minute above a resting heart rate of 80 beats per minute.  
A ROI was then drawn in the basal septum on the 4-chamber view of the resulting 
parametric T1 map, 2 pixels away from the apparent blood:endocardial boundary and were 
drawn without reference to the LGE images.
150 This produced the T1 value which could then 
be converted to the ECV using the same equation described earlier in section 6.10. 
 
7.4.4  LGE: 
Intravenous  Gadoterate  meglumine  (gadolinium-DOTA,  marketed  as  Dotarem® 
Guerbet, S.A., France) was then administered as a 0.1mmol/kg dose via a pressure injector at 
a rate of 3ml/sec, with a 25ml normal saline flush. LGE assessment was then undertaken using 
a FLASH IR sequence with slice thickness 8 mm, TR: 9.8 ms, TE: 4.6ms, α: 21
o, FOV 340 x 220 
mm (transverse plane), sampled matrix size 256 x 115-135, 21 k–space lines acquired every 
other RR interval (21 segments with linear reordered phase encoding), spatial resolution 1.3 x 
2.1 x 8 mm, no parallel imaging, pre-saturation bands over CSF and any pleural effusions.  
These parameters were optimised according to individual patient characteristics. The 
TI was manually set to achieve nulling of the myocardium between 300 and 440 ms. When 
LGE was observed, images were acquired in phase swap and cross cut to ensure artefact 
elimination. Where the LGE distribution appeared particularly diffuse, a TI scout was used to 
ascertain the specific parts of myocardium with the highest concentration of gadolinium. If 
the participant was struggling with the breath-hold, FISP imaging or IR-SSFP imaging (single 
shot or segmented) was used as an alternative sequence. 
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7.4.5  Post contrast T1 evaluation: 
In  some  studies,  15  minutes  after  the  bolus  was  given,  ShMOLLI  T1  mapping  was 
repeated, from which ECVb was derived. In all studies, an infusion of gadolinium was then 
commenced at a rate of 0.0011mmol/kg/min. At this point, the participant was usually taken 
out of the scanner while the infusion ran over the next 30 minutes. They were then returned 
to the scanner with the infusion continuing to run. Repeat T1 assessment was performed 
using the FLASH IR sequence and in most cases, the ShMOLLI T1 mapping sequence as well, 
from which ECVi was derived. Post contrast ShMOLLI required off-line post-processing before 
the T1 could be calculated.  
 
7.4.6  Off line clinical analysis: 
For  LV  volume  and  mass  analysis,  a  thresholding  technique  was  used.  All  of  the 
amyloid patients in this thesis were analysed by myself; the healthy volunteers were analysed 
by Dr. Daniel Sado and Dr. Viviana Maestrini.  
The  healthy  volunteer  scans  were  reported  by  Dr.  Daniel  Sado  and  Dr.  Viviana 
Maestrini, with authorisation by Dr. James Moon (primary supervisor to both); all patient 
studies  were  reported by  myself  and  Dr.  James  Moon  (primary  supervisor  and  Reader  in 
Cardiology) using international guidelines as the basis for all reporting.
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7.5  BLOOD PRESSURE AND 12 LEAD ECG: 
All patients had their blood pressure (BP) measured at the National Amyloidosis Centre 
on a CareScape™ V100 machine by the nursing staff as part of their routine workup. In the 
healthy volunteer cohort, BP was measured after their CMR scan by Dr. Daniel Sado and Dr. 
Viviana Maestrini using a Mindray™ machine.  
A 12 lead ECG was performed on all patients at the National Amyloidosis Centre on the 
same day as the CMR scan, as part of their clinical work up. The ECG was acquired using a 
calibration of 10 mm/mV and speed of 25 mm/s. Interpretation of the trace was performed by 
myself.  Healthy volunteers followed an identical protocol.  
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7.6  BLOOD TESTS: 
All  participants  had  blood  tests  taken  prior  to  the  CMR  scan  at  the  National 
Amyloidosis Centre as part of their clinical workup. This included NT-proBNP and serum free 
light chain in all cases, with Troponin T in just over half the cases as this is only routinely 
performed on new patients. 
 
7.7  SIX MINUTE WALKING TEST (6MWT): 
This was performed at the Heart Hospital along a  flat corridor in accordance with 
current guidelines.
152 Patients were asked to walk a 30-metre length of the corridor at their 
own pace while attempting to cover as much ground as possible in the 6-minute period. 
Verbal encouragement was given using either of 2 standardised phrases: ‘‘You’re doing well’’ 
or ‘‘Keep up the good walk.’’ At the end of 6 minutes, participants were asked to stop and the 
distance covered was recorded. Any symptoms were recorded, as was the Borg score (on a 
scale of 1-10) to assess the degree of breathlessness.
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7.8  ECHOCARDIOGRAPHY: 
In  all  patients,  transthoracic  echocardiography  was  performed  at  the  National 
Amyloidosis Centre on a Philips® IE33 machine as a part of the routine clinical work up. Echo 
studies, included tissue doppler just above the mitral valve annulus at the septal and left 
ventricular  lateral  wall.  Scans  were  performed  and  analysed  by  2  echocardiographers 
experienced  in  scanning  patients  with  cardiac  amyloidosis.  Accepted  markers  of  diastolic 
dysfunction i.e. isovolumic relaxation time (IVRT), E-deceleration time and E:E’ ratio were all 
measured.
154 Echocardiography was not used to assess left ventricular systolic function for 
this work, as CMR was seen as the gold standard in this regard.
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7.9  SAP SCINTIGRAPHY: 
All AL amyloid patients underwent SAP scintigraphy at the National Amyloidosis Centre 
as part of their routine workup. A weight adjusted dose of purified human SAP component, 
radiolabelled with 200MBq of 
123I is injected into the patient. Anterior and posterior whole Page 60 of 150 
body, planar images are captured on a General Electric (GE)® Infinia gamma camera no less 
than 6 hours after the injection. Total amyloid load in the liver and spleen were graded by 
Prof. Philip Hawkins, who has the most experience in reporting these scans in the UK, having 
co-invented the scan with Prof. Sir Mark Pepys in 1988. Grading criteria were as follows:  
  None – No tracer uptake into organs. Normal blood pool signal.  
  Small – Tracer uptake into organs with blood pool still clearly visible 
  Moderate – Tracer uptake into organs with blood pool only just visible 
  Large – Tracer uptake into organs with no blood pool visible 
 
7.10  DPD SCINTIGRAPHY: 
Most of the ATTR patients had DPD scans (instead of SAP scans) by the time of their 
appointment though this was not always possible because of time and scanner limitations on 
the day. Where performed, patients were scanned using a GE® Medical Systems hybrid SPECT-
CT gamma camera (Infinia Hawkeye 4) following administration of 700MBq of intravenously 
injected 99mTc-DPD. Three hour (delayed) whole body planar images were acquired followed 
by a single photon emission computed tomography (SPECT) of the heart with a low-dose, non-
contrast CT scan.   
Gated/non-gated  cardiac  SPECT  reconstruction  and  SPECT-CT  image  fusion  was 
performed on the GE Xeleris workstation. Cardiac retention of 99mTc-DPD was visually scored 
according to the classification described by Perugini et al
84 as follows: Grade 0 - no visible 
myocardial uptake in both the delayed planar or cardiac SPECT-CT scan; Grade 1 - cardiac 
uptake on SPECT-CT only or cardiac uptake of less intensity than the accompanying normal 
bone distribution; Grade 2 – moderate cardiac uptake with some attenuation of bone signal; 
and Grade 3 – strong cardiac uptake with little or no bone uptake. 
 
7.11  STATISTICAL ANALYSIS: 
All statistical analysis was performed by myself using SPSS (IBM Corp. Released 2012. 
IBM  SPSS  Statistics  for  Windows,  Version  20.0.  Armonk,  NY:  IBM  Corp),  except  survival 
analysis which was performed by Aviva Petrie, Head of Biostatistics at the Eastman Dental 
Institute, UCL, using SPSS (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version Page 61 of 150 
21.0. Armonk, NY: IBM Corp) and Stata (StataCorp. 2011. Stata Statistical Software: Release 
12. College Station, TX: StataCorp LP) and my colleague Dr. Gabriella Captur using REDCap 
(Research  Electronic  Data  Capture)  electronic  data  capture  tools  hosted  at  the  University 
College London.
155 
Normality  was  tested  using  the  Kolmogorov  Smirnov  test.  All  continuous  variables 
were  approximately  normally  distributed  except  BNP  and  Troponin  T  which  were  log 
transformed to achieve normality for further analysis. Bivariate analysis compared ECV and 
pre-contrast T1 with all continuous variables. Pearson’s correlation coefficients are presented 
unless  otherwise  stated.  Means  are  presented  ±  SD.  All  reproducibility  for  cardiac  ECV  is 
presented in the form of intraclass correlation coefficients (ICC). Agreement was ascertained 
using  the  Bland-Altman  method  where  results  are  presented  as  mean  bias  ±  2SD.  For 
interstudy reproducibility of liver and spleen ECV, only agreement by the Bland Altman and 
Pearson’s correlations are given. 
The Chi-squared test was used to compare categorical variables between patients and 
controls whilst the unpaired t-test was used to compare continuous variables between the 
patients and controls. A one-way ANOVA with Bonferroni correction was used to test ECV with 
pre-test clinical probability of cardiac involvement described in section 7.2. 
Liver, spleen and muscle ECV measurements in healthy volunteers followed a non-
Gaussian distribution and were compared with those in the Amyloidosis population using a 
Mann-Whitney U test. In order to examine an association between ECV and SAP score in the 
liver  and  spleen,  a  Spearman  correlation  analysis  computing  a  one  tailed  P-value  was 
performed.  
A goal of this study was to assess the prognostic value of myocardial pre contrast T1 
and ECV in Systemic AL Amyloidosis, more specifically the capacity of ECVi compared to ECVb 
and  pre  contrast  T1  for  discriminating  between  surviving  and  dying  patients  with  AL 
amyloidosis.  ROC  curves  provide  a  graphical  display  for  addressing  this  question  by 
characterizing the distribution of measurements among patients that die by time t, relative to 
the distribution of the parameter among patients that survive. However, conventional ROC 
analysis could not be performed because the follow up period was not the same for each 
patient. Therefore, time-dependent ROC curves
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compared to ECVb and pre contrast myocardial T1 for discriminating between surviving and 
dying  patients  with  AL  amyloidosis.  For  fixed  times  (t  =  12  months,  t  =  24  months)  and 
specificity level, we have compared the sensitivity of ECVi, ECVb and pre contrast myocardial 
T1  measurements  for  detecting  patients  that  will  die  by  time  t.  For  the  ROC  curves 
constructed  using  the  nearest  neighbour  estimator  (NNE),  we  used  a  narrow  span  of  λ 
(0.25*nobs^(-0.20)) to yield only moderate smoothing. To permit comparison of ROCs by NNE 
estimator, a set of simple KM estimator ROC curves for this data at t = 24 months were also 
created (see chapter 14 later).   
Survival was evaluated using Cox proportional hazards regression analysis, providing 
estimated hazard ratios (HR) with 95% confidence intervals (CI) and Kaplan Meier curves. 
Linear  regression  models  measured  the  association  between  quantitative  ECV  and  other 
variables; variance inflation factors (VIF) <3 excluded collinearity. Optimal myocardial T1 and 
ECV values were explored by Cox regression, using the median and the 1
st or 2
nd tertiles as 
cut-off values. The two groups resulting from each cut-off were compared using the Harrell’s C 
statistic (a measure of discrimination between groups) in order to determine the better model 
and thus biomarker for predicting survival. All variables were first explored with univariate 
Cox  regression.  Multivariable  models  evaluated  the  independent  predictive  value  of  ECV 
above other clinically and statistically significant covariates.  
For the follow up study, the Wilcoxon Signed Rank Test was used to detect statistically 
significant differences in continuous scale cardiac variables between response groups whilst 
the McNemar’s test detected statistically significant differences in discrete variables between 
response groups. For each patient, amyloid mass was calculated multiplying the ECV x LV mass 
whilst cell mass was calculated by multiplying (1-ECV) x LV mass. Difference in amyloid mass 
and myocyte cell mass was calculated by subtracting follow-up values from the baseline value. 
As  these  differences  were  non-normally  distributed,  results  are  presented  as  median  and 
interquartile  range.  Comparison  between  responder  groups  is  assessed  using  the  non-
parametric Kruskal Wallis test. 
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8.  RESULTS 
 
8. Myocardial ECV as measured by EQ-CMR in Systemic AL Amyloidosis: 
This chapter is based on the publication below:
150 
Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, Cox AT, Fontana M, 
Whelan CJ, Wechalekar AD, Hawkins PN, Moon JC. “Quantification of myocardial extracellular 
volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic 
resonance study.” Circ Cardiovasc Imaging. 2013; 6(1):34-9 
My contribution was consenting, recruiting and scanning all the patients as well as reporting 
and analysing all the data. I also wrote the paper.  
8.1  Introduction: 
As stated earlier in chapter 6, cardiac involvement is the principal driver of prognosis in 
this condition and can be the presenting feature of the disease.
31 Whilst a constellation of 
ECG,  echocardiographic  and  biomarker  findings  becomes  increasingly  diagnostic  and 
prognostic as cardiac amyloidosis progresses, evaluation of early stage cardiac involvement 
can be challenging.  
Concentration of the serum biomarkers NT-proBNP and Troponin T form the basis of 
the Mayo Staging classification
33 but are influenced by renal impairment which is present in a 
quarter of patients at presentation. ECG criteria, low limb lead voltages
23 or fragmented QRS 
complexes
157 are also predictive, but are confounded by pericardial effusions and conduction 
abnormalities. Echocardiographic parameters also predict
59, 158, 159 but other co-existing causes 
of LVH or diastolic impairment affect interpretation.  
Definitive diagnosis of cardiac amyloidosis, which has critical implications for choice of 
chemotherapy  and  management  generally,  requires  cardiac  biopsy  which  is  invasive  and 
prone to sampling error. There are currently no non-invasive tests that can quantify cardiac 
amyloid deposits, the need for this having intensified lately with the development of novel 
anti-amyloid therapies that will shortly need testing and validation.
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New imaging modalities are showing promise; DPD scintigraphy, discussed earlier in 
section 6.4.4, appears to be able to image cardiac amyloid, though chiefly transthyretin (ATTR) 
type,
83 whilst imaging with CMR is virtually pathognomonic of amyloid in some patients when 
the  characteristic  global,  subendocardial  late  gadolinium  enhancement  occurs.
89  However, 
neither is quantitative.  
We  therefore  tested  whether  EQ-CMR  would  accurately  measure  the  degree  of 
interstitial expansion within the heart. 
 
8.2  Hypotheses: 
(1) That EQ-CMR will show a higher ECV in amyloidosis compared to healthy volunteers 
(2) That EQ-CMR will be an effective method for quantifying and tracking cardiac amyloid 
burden.  
 
8.3  Methods: 
Sixty patients from the total AL cohort of 100 mentioned in section 7.2 were recruited. 
Four patients who were found to have AF/flutter after they had consented were not excluded. 
Of  this  cohort,  7  (12%)  patients  were  on  treatment  for  hypertension  and  6  (10%)  had 
confirmed coronary artery disease by angiography.  
All patients were required to have histological proof of systemic AL amyloidosis by 
Congo  red  histology  and  immunohistochemical  staining,  which  was  obtained  through 
specimens  of  kidney  (n=17),  endomyocardium  (n=4),  bone  marrow  (n=8),  upper 
gastrointestinal tract (n=4), liver (n=1), fat (n=6), spleen (n=1), lung (n=1), rectum (n=8), soft 
tissues (n=8), lymph node (n=1) and peritoneum (n=1). This is summarised in figure 23 on the 
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Figure 23: Pie chart showing distribution of tissue biopsies within the patient cohort (n=60). 
 
Healthy subjects (n=82) were the comparator group. As described in sections 7.2 and 
7.3, all patients and healthy controls underwent 12 lead ECG.  Patients additionally underwent 
assays of cardiac biomarkers (NT-proBNP and Troponin T), echocardiography, SAP scintigraphy 
including measurement of total body amyloid load, and a 6-minute walk test, although this 
was not possible in some patients (n=23, 38%) mainly due to other co-morbid factors (e.g. 
arthritis, postural hypotension, peripheral neuropathy) and patient choice. NYHA class and 
ECOG status were also assessed using a standard questionnaire.  
All  patients  underwent  EQ-CMR  using  the  FLASH  IR  method  of  T1  measurement 
outlined in section 6.10 and 7.4. A ROI was drawn in the basal septum of the resultant piloted 
4-chamber image in all patients as shown in figure 17 on page 46 earlier in this thesis; ROIs 
were mid myocardial and excluded subendocardial LGE.  Where gadolinium was present, it 
was often extensive and therefore impossible to exclude from the ROI (see figure 24 on the 
next page). However, where possible, ROIs were also drawn in LGE –ve areas as well as LGE 
+ve areas to determine ECV in both. Reproducibility testing was performed as described in 
section 7: intrastudy (n=11), interobserver (n=11) and interstudy (n=6) scans were analysed by 
myself and Dr. Viviana Maestrini. 
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Figure 24: (A) Standard 4-chamber FLASH LGE image; (B) FLASH T1 measurement image at TI of 200ms, 
demonstrating the difficulty in avoiding areas of LGE when drawing ROIs in cardiac amyloidosis.  
 
Standard  CMR  parameters  of  structure  (LV  mass,  left  atrial  (LA)  area with/without 
indexing, septal thickness), systolic function (EF, MAPSE, TAPSE) were assessed as well as ECV 
calculations. Diastolic function was assessed by echocardiography as described in section 7.8. 
Mean ECG QRS voltage in limb and praecordial leads were calculated.
160  
All statistical analysis was performed as described earlier in section 7.11.  
 
8.4  Results: 
Baseline patient and healthy control characteristics are shown in the table 2 on the 
next page. Patients were older than healthy volunteers and contained proportionately more 
males  than  females.  This  slightly  increases  the  control  group  ECV  compared  to  that  of  a 
gender  matched  group  (see  later  in  this  thesis)  but  there  was  no  statistically  significant 
increase in ECV with age in the healthy controls. 
Patients generally had smaller cavity ventricles and a higher LV mass than healthy 
volunteers. Renal function was slightly more impaired compared to healthy volunteers but EF 
was not statistically significantly different.  
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Characteristic:  Patients:  Healthy volunteers:  P value 
Male /female    39/21  41/41  P=0.08 
Mean Age ± SD (yrs)  62 ± 10  46 ± 15  P<0.001 
Mean Creatinine ± SD (mmol/L)  84 ± 26  74 ± 13  P=0.006 
Median NT-pro BNP in pmol/L (IQ range)  121 (20-272)  -   
Organ involvement 
Peripheral/autonomic neuropathy (%)  14 (23)  -   
Renal involvement (%)  30 (50)  -   
Cardiac involvement: 
None (%) 
Probable (%) 
Definite (%) 
 
15 (25) 
15 (25) 
30 (50) 
 
- 
- 
- 
 
Echocardiography/CMR indices 
Mean Indexed LVEDV ± SD (mls)  60 ± 13  72 ± 12  P<0.001 
Mean Indexed LVESV ± SD (mls)  19 ± 8  23 ± 7  P<0.001 
Mean EF ± SD (%)  67 ± 11  67 ± 5  P=0.44 
Mean Indexed LV mass ± SD(g/m
2)  94 ± 34  66 ± 13  P<0.001 
AF /atrial flutter (%)  4 (7)  0   
Table 2: Showing patient characteristics and differences between AL amyloidosis patients and healthy 
volunteers 
 
The  mean  ECV  in  patients  with  systemic  amyloidosis  was  significantly  elevated 
compared to healthy controls (0.400 vs 0.254, P<0.001). Mean ECV increased between groups 
(P<0.001)  from  healthy controls to  AL  with  no  suspected  cardiac  involvement  (mean  ECV 
0.276),  possible  cardiac  involvement  (mean  ECV  0.342)  and  definite  cardiac  involvement 
(mean ECV 0.488) (figure 25 on the next page).  Page 68 of 150 
 
Figure 25: Relationship between myocardial ECV and pre-test probability of cardiac AL amyloidosis 
demonstrated by (A) Bar graph showing mean +/- SD and (B) Individual plots in bins of 0.02 for ECV on 
y-axis.  
ECV and LGE: 
LGE  prevalence  overall  was  35/60  (58%).    The  pattern  of  LGE  was  global,  sub-
endocardial (n=21), patchy (n=7) and extensive (n=7) (see figure 6 on page 32 for illustrations). 
There was no significant difference in the mean ECVs between these groups. LGE presence 
was strongly tied to the pre-CMR likelihood of cardiac involvement: no, possible, definite 
cardiac  involvement  LGE  prevalences  were  0/15  (0%),  6/15  (40%)  and  29/30  (99%), 
respectively (P<0.001).   
ECV correlated strongly with the presence of LGE (P<0.001). All patients with LGE had 
an elevated ECV. In 4 cases, sufficient LGE negative areas existed to permit additional LGE 
negative ROIs to be drawn.  In these cases, the ECV was lower than that derived from adjacent 
LGE areas, but still demonstrated substantial elevation. (0.45, 0.44, 0.37 and 0.50 compared 
with  0.46,  0.50,  0.44  and  0.53  respectively).  Of  the  25  patients  without  LGE,  6(24%)  had 
elevated ECV, suggesting earlier detection using ECV measurements. 
ECV and LV Structure / Function: 
ECV correlated with CMR cardiac parameters of LV mass, septal thickness, size (LVESV 
and LVESVi) and LAA (see figure 26 on the next page). These findings are summarised in table 
3 on page 71.   
P<0.001 
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Figure 26: Graphs showing the linear relationship between myocardial ECV and (A) Indexed LV mass; 
(B) Septal thickness; (C) Indexed LV end-systolic volume; (D) Indexed LA area in systemic AL 
amyloidosis 
 
 
Figure 27: Graphs showing the relationship between myocardial ECV and (A) Ejection fraction; (B) 
TAPSE; (C) E:E’ and (D) Mitral E wave deceleration time in systemic AL amyloidosis. 
A  B 
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Measures  of  cardiac  systolic  and  diastolic  function  by  CMR  and  echocardiography 
respectively,  including  both  simple  (MAPSE  and  TAPSE)  and  advanced  (TDI  S-wave,  E/E’) 
parameters, also showed correlations (see figure 27 on the previous page and table 3 on the 
next  page);  interestingly,  hypertrophy  was  not  necessary  for  ECV  elevation  -  4  patients 
without hypertrophy (2 of whom had LGE) had raised ECVs (0.34, 0.35, 0.42 and 0.52).   
ECV and other parameters: 
ECV correlated with the biomarkers NT-proBNP and Troponin T (see table 3).  ECV was 
inversely correlated with mean QRS voltage, particularly in the limb leads (limb leads, R=0.57, 
P<0.001; praecordial leads, R=0.30, P=0.02). (See also figure 28 below and table 3 on page 71).  
 
Figure 28: Graphs showing positive, linear relationship between myocardial ECV and (A) Log (base E) 
BNP; (B) Troponin T and inverse relationship between ECV and ECG (C) Limb lead and (D) Chest lead 
voltage, in systemic AL amyloidosis. (Note: fewer values for Troponin T as this test was not routinely 
performed in follow up patients as stated in section 7.6 earlier in this thesis).  
 
Performance  in  the  6MWT  among  patients  with  possible  and  definite  cardiac 
involvement by conventional assessment was poorer than for those with no suspected cardiac 
involvement (218 vs 207 vs 265m, both P=0.01). ECV weakly correlated with 6-minute walk 
A  B 
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test (R=0.36, P=0.03). There were no differences of ECV with NYHA class or ECOG class. These 
results are summarised in table 3 below.  
ECV compared against:  R  P-value 
LV Structure by CMR 
LV mass  0.52  P<0.001 
Indexed LV mass  0.56  P<0.001 
Septal thickness  0.56  P<0.001 
LA area  0.40  P=0.002 
Indexed LA area  0.49  P<0.001 
LV Systolic Function by CMR 
Ejection Fraction  0.58  P<0.001 
MAPSE  0.58  P<0.001 
LV end-systolic volume  0.52  P<0.001 
Indexed LV end-systolic volume  0.56  P<0.001 
TDI-S wave  0.52  P<0.001 
LV Diastolic Function by Echo 
E:E’  0.47  P<0.001 
IVRT  0.36  P=0.03 
E-Deceleration time  0.48  P<0.001 
RV Structure & Function by CMR 
RV end-systolic thickness  0.40  P=0.005 
TAPSE  0.50  P<0.001 
Functional Assessment 
6-minute walk test  0.36  P=0.03 
Biomarkers 
Serum NT-pro BNP (logBNP)  0.69  P<0.001 
Troponin T  0.53  P=0.006 
ECG 
ECG Limb Lead mean voltage  0.57  P<0.001 
ECG chest lead mean voltage  0.30  P=0.02 
Table 3: Showing Pearson’s R correlation coefficients and P-values for relationship between myocardial 
ECV and standard cardiac parameters in systemic AL amyloidosis 
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Reproducibility: 
The ICC for intrastudy reproducibility of cardiac ECV measurement was 0.99 (0.96-
0.99) with a bias of 0.002 (-0.009 to +0.014). The ICC for interobserver reproducibility was 
0.92 (0.76-0.98) with a bias of 0.01 (-0.01 to +0.04). For interstudy reproducibility, the ICC for 
myocardial ECVs was 0.96 (0.90-0.99) with a bias of 0.02 (-0.03 to +0.07). 
 
8.5  Discussion: 
Amyloidosis is the exemplar of an interstitial disease, the quantity of amyloid in the 
extracellular space amounting to kilograms in some patients. Cardiac involvement is a major 
cause of morbidity and mortality, particularly in AL type, but there are currently no non-
invasive methods to quantify it.   
Here,  the  ECV  was  measured  using  EQ-CMR  in  systemic  AL  amyloidosis.  ECV  was 
massively  elevated  in  the  patients  with  definite  cardiac  involvement  but  also  significantly 
higher in patients where conventional clinical testing suggested no cardiac involvement, and 
was significantly elevated in a quarter of patients with no LGE.   
Expansion  of  the  myocardial  ECV  represents  a  non-specific  increase  in  free  water 
between myocytes, and occurs in a variety of pathologies including focal and diffuse fibrosis, 
oedema and amyloidosis.  However, the ECV in amyloidosis is higher than in any other disease 
generating diagnostic specificity above a certain threshold – for example, in our previous work 
(n=238) the highest ECV we have found to date in severe AS, DCM or HCM was 0.37 in a 
severe AS patient with previous coarctation repair and a poor LV.
161  Here, the average value 
for definite cardiac AL amyloid was 0.488 with the lowest value being 0.423. We note however 
that the amyloid ROIs frequently included a proportion of areas of LGE, which was excluded in 
the previous study. Nevertheless, this data suggests that ECV can detect disease earlier than 
conventional testing.  
In this study, strong correlations of ECV were also seen with indexed LV mass, LA area, 
septal thickness and CMR markers of LV systolic function, and more modest correlations with 
measurements of diastolic function. The correlations appear to support many conventional 
clinical strategies – for example, that indexed LA area as an excellent indicator of ventricular 
disease, the use of limb lead QRS voltages and the use of NT-proBNP and Troponin T in the 
Mayo clinical staging system.
33  However, biomarker experience shows that single timepoint 
ECV measurement is not the whole picture - post chemotherapy, suppression of light chain Page 73 of 150 
production  may  trigger  a  swift  change  in  NT-proBNP  levels  (usually  falls,  sometimes 
elevation)
78,  80  with  no  ECG  or  echo  changes,  suggesting  that  simple  amyloid  burden 
quantification incompletely reflects myocardial pathology in amyloid.  
Mean  limb,  rather  than  praecordial,  lead  QRS  voltage  on  ECG  showed  an  inverse 
correlation with ECV. Approximately 50% of patients with cardiac AL amyloidosis have low 
QRS voltage (<6mm)
52 which has been attributed to “insulation” of the electrical impulse on 
the surface ECG due to infiltration. However, it is not seen in all patients and increased QRS 
voltages sometimes occur.
53 Cardiac ATTR amyloidosis may have far more wall thickening than 
AL amyloid, yet low voltages may not occur.  Wall thickening in amyloid is the composite of 
myocyte volume and amyloid burden, with myocyte volume being a net balance of myocyte 
death
74,  77  and  hypertrophy.
162  Conventional  testing  (such  as  LV  mass)  measures  the 
composite of infiltration and cell volume.  Further study with EQ-CMR histological calibration 
to derive myocyte volume as well as ECV will be able to answer important questions about the 
biology of cardiac amyloid.   
A significant correlation with ECV was seen with performance in the 6-minute walk test 
but not with NYHA and ECOG performance status, although walking ability in patients with 
systemic amyloidosis can be influenced by many non-cardiac factors including peripheral and 
autonomic  neuropathy,  peripheral  oedema,  pleural  effusions  due  to  nephrotic  syndrome, 
bone pain due to myeloma, and skeletal muscle loss associated with malnutrition. 
In summary, ECV is reproducible and tracked a wide variety of markers of disease 
activity  such  as  cardiac  function  and  blood  biomarkers,  linked  to  patient’s  functional 
performance, and strongly correlated with limb lead ECG complex sizes. These data suggest 
that ECV measurement is picking up infiltration earlier than conventional testing and is a 
direct  measure  of  the  amyloid  burden  with  potential  utility  in  early  diagnosis,  disease 
monitoring, and potentially as a much needed cardiac surrogate endpoint for the various 
promising new therapies for amyloidosis currently in preclinical development and early phase 
clinical trials.
3, 163  
This has recently become particularly relevant with the first-into-man study of the dual 
CPHPC-monoclonal antibody trial being run by GSK as described back in section 6.8.2.3 where 
the baseline study demonstrated a dramatic reduction in amyloid load measured histologically 
in the liver and spleen of mice after treatment. The first-into-man study is currently underway Page 74 of 150 
and ECV as measured by EQ-MRI is now a surrogate endpoint in determining response to 
treatment, based on this work, because SAP scintigraphy is no longer useful once circulating 
SAP  has  been  depleted  by  CPHPC  administration.  ECV  is  therefore  the  only  non-invasive 
measure of extracellular compartment (and by inference, amyloid load). 
As stated already, a limitation of this study is the lack of histological correlations. In 
previous work, we have correlated diffuse fibrosis with ECV, but only 4 patients in our present 
cohort had undergone cardiac biopsy, and only one of these was contemporaneous, being 
performed within 4 months of the CMR study.  Precise calibration of ECV with histological 
estimation of amyloid burden is desirable but challenging, as often in this multisystem disease 
other organs are biopsied before cardiac involvement is recognised and other organs are 
easier to sample.  Furthermore,  amyloid is patchy, predisposing to biopsy sampling error.  
Another limitation is that the patient and control populations were not age and sex matched; 
ECV is generally higher in women than men although no significant change with age has been 
observed.
148  
As well as histological calibration, populations with ATTR amyloidosis merit study, as 
do the prognostic implications of ECV measurements and their reproducibility (all addressed 
later in this thesis).  Newer, single breath-hold, T1 measurement techniques permit multislice 
mapping and have potential for whole heart quantification,
145, 164, 165 holding the promise that 
it may be possible to avoid the gadolinium infusion in favour of a dynamic/pseudo equilibrium 
method,  which  would  have  substantial  clinical  advantages  in  terms  of  simplicity  (also 
addressed later in this thesis).   
 
8.6  Conclusion: 
EQ-CMR  using  the  FLASH  IR  method  in  systemic  AL  Amyloidosis  has  potential  to 
become the first, non-invasive quantifier of cardiac amyloid burden. 
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9.  Extracardiac ECV as measured by EQ-CMR in Systemic AL Amyloidosis: 
This chapter is based on the following publication:
166 
Bandula S, Banypersad SM, Sado D, Flett AS, Punwani S, Taylor SA, Hawkins PN, Moon JC. 
Measurement of Tissue Interstitial Volume in Healthy Patients and Those with Amyloidosis 
with Equilibrium Contrast-enhanced MR Imaging. Radiology 2013; 268(3): 858-64 
My contribution was consenting, recruiting and scanning all the patients as well as reporting 
and analysing all the data. I also co-wrote the paper. Authorship reflects a departmental level 
agreement between Radiology at UCLH and MRI at the Heart Hospital.  
9.1  Introduction: 
All organs, not just the heart, are composed of metabolically active cells supported by 
an extracellular framework. In health, this architecture provides the medium through which 
cells  exchange  components  necessary  for  intracellular  metabolism,  and  can  contribute, 
physically and metabolically, to the function of their constituent tissue. In disease, this alters 
such that amyloid infiltration causes expansion of the interstitium and thus organ dysfunction.  
The  liver  and  spleen  are  frequently  affected  in  systemic  AL  amyloidosis.  The  only 
conventional non-invasive quantitative test being SAP scintigraphy, as mentioned previously 
in section 6.5. Interstitial expansion in the liver and spleen can be massive but difficult to 
measure; one reason for this has been an inability thus far to reliably and accurately quantify 
the interstitium. The reference standard of invasive tissue biopsy is limited by its technical 
difficulty, complication rate, and sampling error.
167 There are alternative non-invasive tests,
168 
including  biomarkers  and  tissue  elastography,
169-171  however  these  are  frequently  organ 
specific or suffer from similar sampling error. 
In the previous chapter, we demonstrated how EQ-CMR could be used to calculate the 
interstitial  expansion  in  cardiac  amyloidosis.  We  described  how  this  technique  creates 
equilibrium in gadolinium concentrations between myocardium and blood by use of a primed 
gadolinium infusion. However when the heart is at contrast equilibrium, so too are other 
tissues, excluding privileged sites such as structures behind the blood:brain barrier. This raises 
the possibility of extending the technique from EQ-CMR to EQ-MRI in order to assess the 
extracardiac organs and tissues. Page 76 of 150 
The purpose of this study therefore was to assess liver, spleen and skeletal muscle ECV 
in patients with systemic AL Amyloidosis and healthy volunteers.  
 
9.2  Hypotheses: 
(1) Liver, spleen and skeletal muscle ECV as calculated by EQ-MRI will be greater in systemic 
AL Amyloidosis than in health 
(2) Liver, spleen and skeletal muscle ECV as calculated by EQ-MRI will track abdominal organ 
amyloid burden. 
 
9.3  Methods: 
Sixty-seven patients from the AL cohort described in section 7.2 and 40 healthy volunteers 
were recruited. We attempted EQ-MRI using the FLASH IR method described in section 7.4.3.2 
in all 40 volunteers and 67 amyloidosis patients, but, because of time limitations, patient 
discomfort, breathing and wrap-around artefacts and previous surgical resections, complete 
imaging was available as follows: 
  Liver - 35 healthy volunteers and 56 amyloidosis patients 
  Spleen - 32 healthy volunteers and 48 amyloidosis patients 
  Paravertebral muscle - 34 healthy volunteers and 53 amyloidosis patients.  
Imaging of all 3 tissues was available in 30 healthy volunteers and 46 amyloidosis patients. 
All amyloidosis patients underwent SAP scanning of the liver and spleen as described earlier in 
section 7.9. All SAP scans were graded on a scale of 0 (none) to 3 (large load) as described 
earlier in section 7.9. ECV calculated as previously and all statistical analysis performed as 
described earlier in section 7.11. Interstudy variability for ECV calculations of the liver and 
spleen were tested for 6 patients as described in section 7. 
 
9.4  Results: 
Baseline characteristics: 
As in the last chapter, median age was higher in the patient group at 62 years (range 
40-81) for patients and 45 years (range 24-88) for healthy volunteers (P<0.001). There were Page 77 of 150 
also proportionately more males in the patient group than the healthy volunteers (n=43 vs 
n=18, P<0.001).  
Liver, spleen and muscle ECV were non-normally distributed and ECVs are presented as 
median and interquartile (IQ) range.  
Organ ECV in Health and Amyloidosis: 
Within the healthy volunteer cohort, there was a statistically significant difference in 
individual organ median ECVs: liver ECV was 0.29 (IQ range: 0.27–0.33), spleen ECV was 0.34 
(IQ range: 0.32–0.35) and paravertebral muscle ECV was 0.09 (IQ range: 0.08–0.14), P<0.001 
(see figure 29A).  
In amyloidosis, the median ECVs for each organ also varied significantly: liver ECV was 
0.32  (IQ  range:  0.28–0.37),  spleen  ECV  was  0.39  (IQ  range:  0.35–0.51)  and  paravertebral 
muscle  ECV  was  0.16  (IQ  range:  0.13–0.22),  P<0.001.  We  found  a  statistically  significant 
increase in the ECV in amyloidosis patients compared with healthy volunteers for all organs 
(see figure 29B).  
 
Figure 29: (A) Graph showing Median ECV values in the liver, spleen and paravertebral muscle in 
healthy volunteers and (B) Graph comparing median ECVs of healthy volunteers to AL amyloidosis 
patients for liver, spleen and paravertebral muscle. 
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  Interstudy correlation for the spleen revealed an r
2 was 0.98 with a mean bias of -
0.005 (-0.04 to +0.04) although most of these results were clustered around the normal range 
with only 1 outlier result.  For the liver, r
2 was 0.51 with a mean bias of 0.02 (-0.02 to +0.08).  
ECV vs SAP grade: 
Matched liver ECV measurement and SAP scintigraphy was available in 56 patients. In 
15 cases, SAP imaging demonstrated a congested liver pattern with an increased blood-pool 
signal associated with cardiac failure, and in one case, localization of the tracer was equivocal; 
this left 40 patients who could be assigned a liver SAP grade - 29 patients received a score of 
0, five patients received a score of 2, and six patients received a score of 3. Liver ECV showed a 
positive correlation with SAP score (rs 0.54, P<0.001) (see figure 30A).  
We performed matched splenic ECV measurement and SAP scintigraphy in 48 patients. 
Six cases were excluded because SAP activity was scored as equivocal leaving: 22 patients 
scored 0, eight patients scored 1, seven patients scored 2, and five patients scored 3. As with 
the liver, spleen ECV showed a positive (stronger) correlation with SAP score (rs 0.57, P<0.001) 
(see figure 30B below).  
 
Figure 30: Graphs showing relationship of median ECV plotted against SAP grade for (A) Liver and (B) 
Spleen in systemic AL amyloidosis. 
 
9.5  Discussion: 
In this study, we used equilibrium MR imaging to define ECV in healthy tissues and to 
document variation in ECV between tissues. Such data are vital if ECV is to be used to detect 
pathologic processes. We showed significant differences in a disease process that exemplifies Page 79 of 150 
expansion of the extracellular space (systemic AL amyloidosis), which provides strong proof 
that the equilibrium techniques can be successfully applied outside the heart.  
Some pharmacokinetic model based ECV estimates exist. Levitt collected data from 
earlier  experiments  to  produce  a  physiologic-based  pharmacokinetic  model  by  allowing 
estimation  of  the  ECV  in  organs  of  a  hypothetical  standard  human.  He  estimated  the 
extracellular fluid fraction of the liver and muscle to be 0.23 and 0.15, respectively.
172  
More  recent  studies  used  dynamic  contrast-enhanced  MR  imaging  to  quantify  the 
extracellular space and evaluate changes in response to treatment with a tumour disease 
model.
173 Dynamic contrast-enhanced MR imaging is a complex technique that is prone to 
substantial measurement error, and application is limited to only one tissue site.
174 A direct 
comparison of equilibrium MR imaging and dynamic contrast-enhanced MR imaging ECV has 
not  yet  been  made;  however,  other  authors  who  used  dynamic  contrast-enhanced  MR 
imaging  reported  ECVs  of  0.2–0.3  in  healthy  liver
175  and  ECVs  of  0.106–0.115  in  skeletal 
muscle.
176  The  estimates  of  ECV  from  pharmacokinetic  modelling  and  dynamic  contrast-
enhanced MR imaging are consistent with each other and with our equilibrium MR imaging 
results.  
In this study, we compared a disease-specific, in-vivo probe for extracellular amyloid 
deposition.  SAP  scintigraphy  is  the  current  reference  standard  for  evaluation  of  systemic 
amyloidosis  and  has  enabled  wider  assessment  of  organ  amyloid  involvement.  Unlike 
histological analysis, SAP scintigraphy can be used to monitor changes in whole organs over 
time. These results demonstrated that an increase in tissue amyloid burden, assessed by SAP 
scintigraphy,  was  associated  with  an  increase  in  tissue  ECV.  Therefore,  equilibrium  MRI 
imaging may be a useful non-invasive tool for amyloid assessment and potentially therapeutic 
monitoring with the added advantage of not exposing the patient to radiation.  
Disease evaluation and quantification with SAP scintigraphy requires specific expertise, 
and it is only available in highly specialized centres. As described in sections 6.4.4 and 6.5 
earlier, the high atomic mass of the SAP molecule (125 kDa) also favours evaluation in tissues 
with a fenestrated endothelium, such as the liver and spleen, where the large molecule is able 
to  pass  into  the  interstitium.  Hence,  SAP  scintigraphy  provides  little  information  about 
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This  study  had  several  limitations.  The  FLASH–based  T1  mapping  technique  is 
complicated  and  time-consuming.  Although  the  bolus-with-infusion  protocol  used  in  this 
study provided steady-state equilibrium in all tissues of interest, prolonged contrast infusions 
are not practical for clinical imaging. Our preliminary experimental findings concur with other 
authors’ findings by showing that steady-state equilibration is reached approximately 15 to 20 
minutes  after  administration  of  contrast  bolus  with  infusion.
147  Future  protocols  may 
incorporate equilibrium-phase imaging after a shorter delay.  
The ideal comparator for this study would have been histological assessment of the 
liver extracellular space. Histological techniques to quantify extracellular collagen matrix do 
exist; automated collagen proportionate area measurement showed good association with 
other  indices  of  diffuse  liver  fibrosis  when  applied  to  the  liver.
177  However,  collagen-
proportionate area measurements in the healthy liver are around 2%–3%,
178 which is much 
lower than our ECV estimate. This difference is most likely because the extracellular collagen 
matrix  occupies  only  part  of  the  extracellular  space  within  the  liver.  Current  histological 
techniques are unable to directly measure the ECV because the process of tissue sampling and 
preparation almost certainly alters tissue ECV.  
Equilibrium MRI evaluation of ECV is not specific to an aetiological class of disease. In 
addition to amyloid deposition and diffuse fibrosis, tissue ECV may be elevated by interstitial 
oedema or an inflammatory infiltrate. Although these potential confounders could not be 
specifically excluded in this study, cases that demonstrated a congested pattern of activity on 
SAP scintigraphy were excluded from the SAP and ECV correlation.  
It should be noted that healthy volunteer and amyloidosis patient groups were not 
matched  for  age  or  sex.  As  mentioned  in  the  previous  chapter,  mean  myocardial  ECV  in 
healthy women is around 4% higher than in healthy men but there is no change with age.
148 
This has not been assessed in other organs. In this study, the higher ratio of women in the 
healthy  group  (18  men,  22  women)  compared  with  the  amyloidosis  group  (43  men,  24 
women) may have reduced the difference in mean ECV measured between these groups. To 
minimize such bias, future studies should ensure that groups are matched for sex.  
Although we assessed equilibrium MR imaging in one disease, it is worth noting that 
amyloidosis  forms  part  of  a  larger  set  of  conditions  where  extracellular  disruption  and Page 81 of 150 
expansion  leads  to  organ  dysfunction  e.g.  liver  cirrhosis.  The  application  of  equilibrium 
imaging in these organs could potentially provide a new biomarker for disease evaluation 
 
9.6  Conclusion: 
EQ MRI allows ECV of abdominal organs to be calculated; ECV is higher in systemic AL 
amyloidosis compared to healthy volunteers and tracks organ amyloid burden.  
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10.  Technical Development – Refining Clinical Applicability: 
My contribution was consenting, recruiting and scanning all the patients as well as reporting 
and analysing all the data as first operator. I supplied the entire amyloid component of the 2 
technical development papers which I co-wrote with other colleagues within the department 
during the time of my MD.
179, 180  
 
10.1  Introduction: 
In the previous two chapters 8 and 9 in this thesis, we have shown how the EQ-CMR 
method uses high resolution FLASH-IR sequences at increasing inversion times to produce a T1 
measurement for heart, blood, liver, spleen and skeletal muscle. The ECV is then calculated as 
previously described in section 6.10. This technique has advantages in that it is not vendor 
specific and is used in everyday clinical practice to obtain high resolution late gadolinium 
enhancement images. 
However, there are a number of factors which limit its clinical utility in the current 
format. Firstly, there exist a number of ways where error may be introduced; patients are 
frequently short of breath, not only from the cardiac dysfunction due to amyloidosis, but also 
as  a  result  of  pleural  and  pericardial  effusions.  The  FLASH  method  of  T1  measurement, 
although high resolution, can be a problem for many patients because of the length of time 
required to breath-hold for one sequence; add to this that there are 9 sequences for the heart 
with a further 9 sequences repeated for the liver and spleen. This leads to image degradation 
because of breathing artefact as well as “ghosting” from the effusions. Indeed, the worst case 
scenario is patients being unable to undergo the research sequences at all.  
Secondly, because it is a multi breath hold technique,  patients may take a slightly 
different breath-hold with each sequence, altering not only position of the resultant image, 
but also affecting the R-R interval during the breath-hold (NB: a relatively stable R-R interval is 
necessary to accurately apply the heart rate correction).  Furthermore, once the images have 
been obtained, the post processing is laborious, involving drawing a ROI on multiple images 
and a manual curve fit to the data points to calculate the TI of interest, plus correction, as 
extensively described in section 6.10. It is also ideal to try and avoid areas of LGE where 
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Finally, there is the issue of the cumbersome gadolinium infusion. We calculate the 
ECV using the formula outlined in section 6.10. This formula holds true as long as a steady-
state  equilibrium  of  gadolinium  concentration  exists  between  the  plasma  and  the  tissue 
extracellular space i.e. elimination of the normal gadolinium kinetics (see figure 18 in section 
6.10). We achieve this with EQ-CMR using a primed infusion of gadolinium commenced at 
15mins post bolus. Recent work however, suggests that a “window of opportunity” may arise 
at 15mins post bolus, where a dynamic equilibrium or “pseudoequilibrium” may exist because 
renal excretion of gadolinium is slower than the free movement of gadolinium between blood 
and tissue extracellular compartments.
165, 181 Imaging (T1 mapping) at this time may allow an 
accurate ECV to be calculated, saving approximately 45 minutes per scan, and sparing the 
patient from 30 minutes of a 0.0011 mmol/kg/min infusion of gadolinium; such a technique 
would  clearly  greatly  enhance  the  applicability  of  ECV  assessment  further  in  the  clinical 
setting.  
However,  there  are  concerns  that  if  the  timing  of  the  image  acquisition  is  not 
consistently  accurate,  that  this  would  adversely  affect  the  resultant  ECV;  the  ECV  does 
gradually rise linearly with time as a result of normal gadolinium kinetics.
182 Moreover, this 
bolus only technique has only been tested in healthy volunteers
181 and only very recently in 
some  cardiac  disease  states.
183  It  has  crucially  not  been  tested  in  patients  with  systemic 
amyloidosis which adds its own, almost unique, set of problems because of how amyloid 
affects normal gadolinium kinetics; normally and in most disease states, it is the blood and not 
the myocardium which has the highest concentration of gadolinium in the first few minutes 
after the bolus injection - in cardiac amyloidosis however, the opposite is observed.  Whilst 
the mechanism for the observation is unclear, it is thought that a high free water content 
within the amyloid matrix in the heart, rapidly extracts gadolinium from the plasma into the 
myocardial interstitium – this produces the pathognomonic reversed nulling seen on TI scouts 
as described in section 6.4.5.  
This chapter therefore first evaluates how the FLASH T1 measurement technique was 
made more clinically applicable by reducing breath-hold times for the patients by using the 
ShMOLLI  T1  mapping  sequence  recently  devised  by  Oxford.  Finally,  I  describe  how  the 
technique was further refined by removal of the gadolinium infusion whilst still maintaining 
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10.2  Hypotheses: 
1. ECV derived using the ShMOLLI technique will closely match ECV derived from the FLASH 
technique. 
2. ECV derived without a gadolinium infusion (ECVb) would correlate with ECV calculated using 
the infusion (ECVi) 
 
10.3  Methods: 
10.3.1 Comparison of FLASH ECV vs ShMOLLI ECV: 
Our group acquired the ShMOLLI sequence in 2011, therefore only 50 of the 100 AL 
Amyloid patients outlined in section 7.2 underwent EQ-CMR of the heart using both FLASH IR 
and ShMOLLI T1 mapping methods and 13 of these also had liver and spleen ECV by both 
methods  (n=12  for  spleen  as  1  patient  had  a  splenectomy).  All  scans  were  analysed  as 
described previously and ECV results at equilibrium calculated by myself.  
ShMOLLI ECV results were compared for correlation (Pearson’s) and agreement (Bland 
Altman) with ECVs derived using the histologically validated FLASH technique. 
10.3.2 Comparison of Equilibrium vs Pseudoequilibrium ECV: 
Fifty-one patients from the AL Amyloid cohort described in section 7.2 underwent full 
EQ-CMR with ShMOLLI T1 mapping and all patients additionally had a ShMOLLI T1 map at 15 
minutes post bolus. The T1 was measured in the basal septum in the 4-chamber slice and in 
aortic blood and the mean cardiac ECVb and ECVi calculated. Bland Altman analysis was used 
to assess agreement between the 2 methods and Pearson’s correlation coefficient used to 
assess correlation.  
 
10.4  Results: 
10.4.1 Comparison of FLASH ECV vs ShMOLLI ECV: 
There was a correlation between FLASH and ShMOLLI ECV for the heart with an R
2 of 
0.86. Tests for agreement showed a bias of -0.03 (-0.13 to +0.05) for FLASH. All values except 
1 fell within the 2 SDs (see figure 31 below): Page 85 of 150 
 
Figure 31: FLASH vs ShMOLLI reproducibility (Left) Scatterplot showing the correlation of the 2 
myocardial ECVs; (right) Bland Altman graph showing agreement of the 2 myocardial ECVs. 
 
Liver ECV by FLASH also correlated well with ShMOLLI values with an R
2 of 0.80. There 
was good agreement between the 2 methods with a bias of -0.04 (0.12 – 0.03) for FLASH. As 
above, all values except 1 fell within the 2 SDs (see figure 32 below).  
 
Figure 32: FLASH vs ShMOLLI reproducibility (Left) Scatterplot showing the correlation of the 2 Liver 
ECVs; (right) Bland Altman graph showing agreement of the 2 Liver ECVs. 
 
There was good correlation and agreement between FLASH and ShMOLLI methods for 
ECV of the spleen with an R
2 of 0.95 and a bias of -0.007 (-0.07 – 0.05) for FLASH. Once again, I 
acknowledge that the majority of data points lie at the lower end of the ECV spectrum. All 
values fell within the 2 SD limits (see figure 33 on the next page): Page 86 of 150 
 
Figure 33: FLASH vs ShMOLLI reproducibility (Left) Scatterplot showing the correlation of the 2 Spleen 
ECVs; (right) Bland Altman graph showing agreement of the 2 Spleen ECVs. 
 
10.4.3 Comparison of Equilibrium ECVi vs Pseudoequilibrium ECVb: 
Mean ECVb and ECVi were both 0.45 (SD 0.12). Both correlation and agreement were 
good with a R
2 correlation coefficient of 0.88 and a minimal bias of -0.008 (-0.08 to +0.07) (see 
figure 34 below). The scatter plot shows little spread at ECVs of less than 0.45 and slightly 
wider spread with higher ECVs.  
Bland  Altman  analysis  revealed  an  equal  spread  of  results  above  and  below  the 
identity line with the vast majority of values falling within the 2 SD limits: 
 
Figure 34: ECVi vs ECVb (Left) Scatterplot showing the correlation of myocardial ECVi and myocardial 
ECVb; (right) Bland Altman graph showing agreement of myocardial ECVi and myocardial ECVb. 
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10.5  Discussion: 
Correlation and agreement were assessed between FLASH EQ-CMR and ShMOLLI EQ-
CMR methods of ECV calculations for heart (n=50), liver (n=13) and spleen (n=12) ECV. FLASH 
and ShMOLLI ECV values showed excellent correlation with each other for heart, liver and 
spleen ECV, all yielding an R
2 of ≥ 0.8. Agreement was also very good across heart, liver and 
spleen ECVs with the largest mean difference being 0.04 for liver ECV. This suggests that the 
EQ-CMR using ShMOLLI is an equally accurate method for ECV quantification when compared 
to the histologically validated and current gold standard FLASH method, with the significant 
advantage however of being more patient friendly, having better clinical applicability and 
having a much less laborious off-line analysis. Additionally, interstudy reproducibility has since 
been performed, demonstrating that ShMOLLI ECV carries better reproducibility than FLASH 
ECV (see figure 35 below).
179 
 
Figure 35: Bland Altman graph showing agreement for interstudy reproducibility of myocardial ECVs 
using the ShMOLLI method. Adapted from Fontana M et al
179 
 
We assessed ECVb and ECVi in 51 patients with systemic AL Amyloidosis and compared 
the results for agreement and correlation. There is a strong, linear correlation and strong 
agreement between the 2 values suggesting that ECVb is a comparable marker to ECVi but 
carries  the  significant  advantage  that  it  is  does  not  require  the  infusion  of  gadolinium, 
rendering it a much shorter technique, easier for patients to perform and less cumbersome 
for the operator. It also opens up the practical possibility of whole heart mapping, which Page 88 of 150 
would require only 3 sequences in either long axis or short axis to acquire all 17 segments of 
the heart.  
These  findings  are  contrary  to  other  published  work.  A  study  of  n=20  per  various 
cardiac diseases concluded that in high ECV diseases i.e. > 0.40 (e.g. cardiac amyloid, MI), ECVb 
consistently overestimates compared to ECVi. The bias for ECVb > 0.40 was +0.04, compared to 
-0.004 here for ECVb > 0.40.
180 The study concluded, perhaps because of the large amount of 
amyloid predominating in the subendocardium, that gadolinium was still diffusing into the 
myocardium at 15 minutes rather than being at true equilibrium – hence, a longer wait may 
be necessary to obtain a more accurate ECV. This observation appears now less marked but 
still present as evidenced by the scatter at high ECVs. Ultimately, as a diagnostic tool, ECVb is 
likely to be adequate, but for follow up or research purposes where the most accurate result 
is needed, an infusion may be necessary. 
For  the  FLASH  vs  ShMOLLI  comparison,  there  were  smaller  numbers  for  liver  and 
spleen ECV compared with cardiac ECV. This was because there was initially no expertise 
regarding how to image the liver using the ShMOLLI, as this had only been validated in the 
heart.  Secondly,  there  was  a  brief  period  when  our  department  experienced  a  generic 
problem with imaging the liver due to several artefact problems and ShMOLLI liver maps were 
not performed therefore during this period. This was eventually tracked down to be a broken 
coil element that was causing error despite passing Siemens quality control.  
Finally, ECVb and ECVi have not been validated against histology in amyloidosis. Both 
have been validated against collagen volume fraction in aortic stenosis though. Histological 
validation for systemic amyloidosis remains work in progress. There has been recent evidence 
to support the role of ECVb in prognosis
184 but this will be explored later in this thesis.  
 
10.6  Conclusions: 
1. EQ-CMR using ShMOLLI to calculate cardiac and extracardiac ECV is as accurate in systemic 
AL amyloidosis as the FLASH method, but is much more clinically applicable, reproducible and 
easier to use for patients and operators. Histological validation is required.  
2. ECVb can be used instead of ECVi when assessing systemic AL amyloidosis. Again, 
histological validation is required.  Page 89 of 150 
11.  Pre Contrast T1 mapping in Systemic AL Amyloidosis: 
This chapter is based on the publication below:
185 
Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, 
Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. “Non-Contrast T1 mapping for 
the diagnosis of cardiac amyloidosis.” JACC Cardiovasc Imaging. 2013 Apr;6(4):488-97 
All amyloid patients in this study were AL type and were recruited by myself. All scanning, 
reporting  and  analysis  was  done  by  myself  –  authorship  reflects  the  aortic  stenosis 
contribution to the paper (not included in this thesis) and also a reciprocal department level 
agreement between the Heart Hospital and Oxford for early access to ShMOLLI. 
11.1  Introduction: 
We have so far demonstrated how ECV can be used to quantify organ amyloid burden 
in systemic AL amyloidosis. We have also shown in chapter 10 that the ShMOLLI method of 
acquiring ECV  measurements  is  superior  to  the  original  FLASH  IR  method.  But  this  is  not 
always possible in all patients with systemic AL amyloidosis e.g. severe renal impairment. 
The main advantage of CMR compared to echocardiography is in myocardial tissue 
characterisation, whether that be through the appearance of global subendocardial LGE, the 
hallmark for making the diagnosis of cardiac amyloidosis
90, 93 or with ECV measurements.   
However,  many  of  these  patients  have  significant  renal  impairment  and  so  the 
administration of a gadolinium-based contrast is problematic. Furthermore, the pattern of 
LGE may be atypical and patchy as described in section 6.4.5, particularly in early stages of the 
disease.
90,  91,  186 Therefore, a non-contrast CMR technique that could provide quantitative 
assessment of myocardial amyloid load would prove particularly useful in these patients. 
Measurement of myocardial T1 relaxation times using non-contrast T1 mapping has 
been shown to be useful in the detection of interstitial expansion due to myocardial oedema 
and fibrosis.
187-190 Furthermore, alterations of T1 times in the liver, spleen, and fat in patients 
with systemic AL amyloidosis have been described using low field MRI.
191  
We explored therefore whether non-contrast T1 mapping using the single breath-hold 
ShMOLLI technique would provide diagnostic information in patients with suspected cardiac 
AL amyloidosis. Page 90 of 150 
11.2  Hypothesis: 
That  pre  contrast  T1  mapping  with  the  ShMOLLI  technique  will  provide  adequate 
diagnostic information of the cardiac status in patients with systemic AL amyloidosis.  
 
11.3  Methods: 
  Fifty-three patients with systemic AL amyloidosis and no contraindications for CMR 
were recruited from the cohort described in section 7.2. Histological proof of AL amyloid was 
obtained through specimens of: kidney (n=15), bone marrow (n=8), soft tissues (n=8), fat 
(n=5), rectum (n=5), endomyocardium (n=4), liver (n=2), lymph node (n=2), upper GI tract 
(n=1), lung (n=1), and peritoneum (n=1). See figure 36 below: 
 
Figure 36: Pie chart showing distribution of tissue biopsies within the AL amyloidosis patient cohort 
(n=53). 
 
Four patients who were found to have AF/flutter after they had consented were not 
excluded. Based on the classifying criteria detailed in section 7.2, the amyloid patients were 
characterized as having no (n=14), possible (n=11) and definite (n=28) cardiac involvement. 
Thirty-six normal volunteers from the cohort in section 7.3 were also recruited.  
All subjects underwent pre contrast myocardial T1 mapping with ShMOLLI as part of 
their EQ-CMR where a bolus of 0.1mmol/kg of Dotarem™ was ultimately given as described in Page 91 of 150 
previous  chapters.  All  patients  underwent  echocardiography  for  diastolic  measures  as 
described in section 7.8 and all statistical analysis performed as described in section 7.11.  
 
11.4  Results: 
Patient characteristics are described in table 4. There were no differences in age, sex 
and body surface area between the groups of patients and healthy volunteers. Patients with 
definite cardiac amyloid had significantly increased LV mass index (P<0.001) and smaller LV 
end-diastolic  volume  (P=0.001)  compared  to  healthy  controls.  EF  was  mildly  reduced  in 
patients  with  definite  cardiac  involvement  compared  to  the  other  groups  (P<0.01  for  all 
comparisons) although values remained within normal limits. There were no differences in 
renal function between the 3 groups of systemic AL amyloidosis patients.  
  Normals 
 
 
N=36 
Amyloid: 
No cardiac 
 
N=14 
Amyloid: 
possible 
cardiac 
N=11 
Amyloid: 
definite 
cardiac 
N=28 
P-value 
Age  59 ± 4  58 ± 12  65 ± 10  63 ± 10  0.07 
Gender (M/F)  22/14  8/6  7/4  20/8  0.85 
NYHA class > III (n)  -  0  1  2  - 
eGFR (ml/min/1.73m
2)  NA  85 ± 10  74 ± 32  77 ± 20  0.42 
LVEDV index (ml/m
2)  77 ± 13  59 ± 11  58 ± 9  65 ± 11  <0.001 
LVESV index (ml/m
2)  20 ± 5  16 ± 5  13 ± 5  25 ± 8  <0.001 
EF (%)  74 ± 5  73 ± 6  77 ± 6  62 ±12  <0.001 
LV mass index (g/m
2)  58 ± 11  69 ± 20  77 ± 20  118 ± 32  <0.001 
Table 4: Showing patient characteristics and differences between patients with differing pre-test 
probabilities of cardiac amyloidosis in systemic AL amyloidosis and healthy volunteers. 
 
Mean pre contrast myocardial T1 as measured by ShMOLLI was higher in patients at 1086 
± 90msec, compared to healthy volunteers of 958 ± 20msec (P<0.001). Myocardial T1 times 
showed a stepwise elevation as the probability for cardiac involvement increased: 1009 ± 
31msec without cardiac involvement, 1048 ± 48msec with possible cardiac involvement, 1140 
± 61msec with definite cardiac involvement (see figure 37 on the next page).  
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Between group comparisons are summarized in the list below:  
  Normals vs amyloid without cardiac involvement, P=0.003 
  Normals vs possible cardiac amyloid, P<0.001 
  Normals vs definite cardiac amyloid, P<0.001 
  Amyloid without cardiac involvement vs possible cardiac amyloid, P=0.265 
  Amyloid without cardiac involvement vs definite cardiac amyloid, P<0.001 
  Possible cardiac amyloid vs definite cardiac amyloid, P<0.001 
 
Figure 37: Graph showing the relationship between mean pre contrast myocardial T1 time and pre-test 
probability of cardiac involvement in systemic AL amyloidosis, compared to healthy volunteers.  
 
ROC analysis (see figure 38 on the next page) showed that a  pre contrast myocardial 
T1  cut-off  value  of  1020msec  using  ShMOLLI  T1  mapping  yielded  a  92%  accuracy  for 
identifying cardiac involvement (area under the ROC curve 0.969±0.01, P<0.0001). Based on 
this cut-off, 3 patients with possible cardiac amyloid would have been wrongly classified as 
having no cardiac involvement (sensitivity 92%). In contrast, there are 3 false positive cases: 3 
amyloid patients with no cardiac involvement clinically who have myocardial T1 above the 
threshold (specificity 91%). Page 93 of 150 
 
Figure 38: ROC curve analysis for pre-contrast myocardial T1 times in Systemic AL amyloidosis.  
 
LGE findings and T1 in cardiac amyloid: 
There was no evidence of LGE in the group of AL systemic amyloidosis patients without 
cardiac involvement.  
In  the  group  of  patients  with  possible  cardiac  involvement,  3  patients  had  typical 
circumferential  subendocardial  LGE,  1  patient  had  patchy  enhancement,  2  patients  had 
reversed nulling on T1 scout and 5 patients had no evidence of LGE.   
In  the  definite  cardiac  involvement  group,  1  patient  had  no  evidence  of  LGE,  and 
another one had only abnormal kinetics on T1 scout. All other patients in this group had 
evidence of LGE (9 circumferential subendocardial, 6 patchy, 11 extensive LGE - involving not 
only the subendocardium but also the subepicardial layer).  
All patients with patchy enhancement had increased T1 times (above the threshold of 
1020ms determined by ROC analysis), irrespective of the clinical classification as possible or 
definite cardiac involvement. Furthermore, 2 out of 3 patients with abnormal kinetics on T1 
scout  also  had  elevated  T1  times.  Interestingly,  3  out  of  5  patients  with  possible  cardiac 
involvement but no discernible LGE, had significantly elevated T1 times and this also applies to 
the patients with definite cardiac involvement who had no LGE. Representative examples of 
the CMR scans are shown in figure 39 on the next page: Page 94 of 150 
 
Figure 39: Cine still, ShMOLLI and LGE images from (Top 3) Healthy volunteer; (middle 3) AL 
Amyloidosis patient with extensive LGE; (bottom 3) AL Amyloidosis patient with little LGE 
This image became the front cover of JACC Cardiovascular Imaging, April 2013. 
 
T1 and cardiac function in cardiac amyloid: 
There  were  significant  correlations  between  pre  contrast  T1  relaxation  times  and 
indices of systolic and diastolic function in the AL amyloidosis cohort. EF decreased (R=-0.57, 
P<0.001) and indexed LV mass increased (R=0.58, P<0.001) as T1 times increased, indicating 
that  the  changes  in  myocardial  T1  times  reflect  to  some  extent  the  severity  of  cardiac 
involvement (see figure 40 on the next page). In addition, T1 times increased significantly as 
diastolic function worsened, evidenced by the positive correlation between T1 times and E/E’ 
ratio (R=0.45, P=0.001) and the negative correlation between T1 times and E deceleration 
time (R=-0.44, P= 0.002). See also table 5 on the next page: 
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Figure 40: (Left) Graph showing positive, linear correlation of pre contrast myocardial T1 and indexed 
LV mass; (right) graph showing inverse correlation between pre contrast myocardial T1 and ejection 
fraction in systemic AL amyloidosis. 
 
  Normals 
 
 
N=36 
Amyloid: 
No cardiac 
 
N=14 
Amyloid: 
possible 
cardiac 
N=11 
Amyloid: 
definite 
cardiac 
N=28 
P-value 
ShMOLLI T1 (msec)  958±20  1009±31  1048±48  1140±61  <0.001 
E:A ratio  NA  0.88±0.15  0.97±0.38  1.72±0.81  <0.001 
E:E’ ratio  NA  7.6±2.3  14.2±4.5  15.4±6.4  <0.001 
E dec time (msec)  NA  204±42  231±66  174±62  0.03 
Table 5: Showing pre contrast myocardial T1 values and echocardiographic markers of diastolic 
function for patients according to their pre-test probability of cardiac disease in systemic AL 
amyloidosis and healthy volunteers. 
 
11.5  Discussion: 
This study finds that patients with systemic AL amyloidosis show significantly increased 
pre contrast myocardial T1 values compared to healthy controls. This increase is tied to the 
extent of cardiac involvement and there is increase in T1 times even when involvement is 
uncertain or thought not present.  Furthermore, pre contrast T1 correlates well with markers 
of systolic and diastolic dysfunction, indicating that the changes in myocardial T1 reflect to Page 96 of 150 
some extent the severity of cardiac involvement. T1 mapping appears to be a useful test to 
diagnose cardiac involvement in systemic AL amyloidosis.  
As mentioned already in this thesis in section 6.7, cardiac involvement portends a poor 
prognosis in AL amyloidosis patients. Its detection informs the intensity of therapy in many 
cases. The gold standard for diagnosis of cardiac involvement is cardiac biopsy but sampling 
error prevents quantification and there can be false negatives. As mentioned in chapter 6, 
ECG  abnormalities  such  as  low  QRS  voltages  in  limb  leads  (<0.6mV)  and  poor  R-wave 
progression  in  chest  leads  occur  in  up  to 
2/3  of  cardiac  AL  amyloid  patients.
23,  53 
Echocardiography  may  demonstrate  wall  thickening,  poor  longitudinal  function,  biatrial 
dilatation, early diastolic and late systolic dysfunction,
63, 192 but only in the advanced stage do 
these features become discriminatory over other diseases such as the hypertensive heart.  
CMR  provides  additive  information  in  cardiac  amyloid  via  myocardial  tissue 
characterization with contrast.  The appearance of global, subendocardial LGE and associated 
dark blood-pool is characteristic and correlates with prognosis.
88-91, 93 Other LGE patterns do 
exist  as  described  in  section  6.4.5,  and  LGE  may  occur  even  without  overt  hypertrophy.  
However, LGE patterns may be non-specific or only occur in later disease, and require contrast 
which may be contraindicated in patients with renal failure which is common in amyloid.
193  
With the degree of myocardial infiltration present in amyloid, pre contrast T1 mapping 
has the potential to detect cardiac involvement and be clinically useful.  Changes in T1 times 
had previously been demonstrated in the liver, spleen, and fat in amyloidosis using low field 
MRI
191  and  early  results  supported  myocardial changes.
86,  194,  195  Here,  we  build on these 
results using the latest, robust and more accurate advanced short breath-hold T1 mapping 
technology  incorporating  a  single  output  colour  T1  map
196  in  a  large  cohort  with  robust 
controls and demonstrate functional consequences and early disease detection.  Although 
there are technical differences between the MR sequences used to measure T1 relaxation 
times, our results are in agreement with previous work from Hosch and colleagues who found 
a 19% increase in T1 times in cardiac amyloid patients compared to normal controls.
86  
Measurement of T1 times using ShMOLLI T1 mapping has shown very good accuracy 
for the detection of cardiac involvement in AL amyloidosis and correlate well with the extent 
of systolic and diastolic dysfunction. It is tempting to speculate that pre contrast T1 mapping is Page 97 of 150 
more sensitive than the LGE technique for the detection of cardiac involvement, as all amyloid 
patients with non-typical patchy enhancement had increased T1 values.  
This  study  has  similar  limitations  to  previous  chapters  in  this  thesis,  chiefly  that 
patients  had  histologically  proven  amyloid  but  not  routine  endomyocardial  biopsies.    No 
histological  correlation  with  T1  is  therefore  available.    T1  mapping  is  also  of  course  a 
composite  value  of  myocytes  and  interstitium  and  does  not  therefore  represent  the 
interstitium alone; ECV is the better marker for this. Finally, the prognostic value of T1 values 
in amyloid was not explored here, but this is assessed in the next chapter. 
 
11.6  Conclusion: 
Pre contrast myocardial T1 appears to be a useful test to diagnose the presence and 
extent of cardiac involvement in systemic AL amyloidosis. 
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12.  T1 mapping and Survival in Systemic AL Amyloidosis: 
This chapter is based on the publication below: 
Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, Whelan CJ, Herrey AS, 
Gillmore JD, Lachmann HL, Wechalekar AD, Hawkins PN, Moon JC. “T1 Mapping and Survival 
in Systemic Light Chain Amyloidosis.” European Heart Journal (2015); 36(4): 244-51.
197 
An  abstract  of  this  work  also  won  $500  at  the  Young  Investigator  Awards  finals  at  the 
American Heart Association in Dallas when presented on 17
th November 2013 and was also 
presented at the Young Investigator Awards at SCMR in New Orleans earlier this year on 17
th 
January 2014. My contribution was recruiting all the patients, reporting and analysing all scans 
and writing the paper.  
 
12.1  Introduction: 
As mentioned earlier in chapter 6, cardiac involvement in systemic AL amyloidosis is 
present in around 50% of patients at presentation and is the principal driver of prognosis.
198  
Current  predictors  of  survival  rely  on  measuring  surrogate  rather  than  direct  markers  of 
interstitial  expansion  (e.g.  serum  cardiac  biomarkers).  ECG  criteria  such  as  low  limb  lead 
voltages
23  or  fragmented  QRS  complexes
157  are  also  predictive,  but  are  confounded  by 
pericardial  effusions  and  conduction  abnormalities.    Echocardiographic  parameters  also 
predict outcome
59,  158,  159 but coexisting causes of LVH or diastolic impairment may affect 
interpretation.  
CMR  with  LGE  imaging  adds  value  in  the  diagnosis  of  cardiac  involvement  in  AL 
amyloidosis. Altered gadolinium kinetics also shows some correlation with survival.
93 In this 
chapter therefore, we now consider the predictive power of ECV after primed infusion (ECVi) 
with survival. In addition, we also tested the predictive power of ECVb, pre contrast T1 and 
post contrast T1.   
 
12.2  Hypotheses: 
1. That ECV will correlate with survival 
2. That ECV correlates better with survival than pre contrast and post contrast myocardial T1. 
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12.3  Methods: 
The 100 consecutive patients with systemic AL amyloidosis stated in section 7.2 were 
recruited (this includes all 60 patients in chapter 8 and all 53 patients in chapter 11). Six 
patients, who were found to have AF/flutter once in the scanner after they had consented, 
were not excluded.  
All patients had histological proof of systemic AL amyloidosis except 2 (2%), who died 
before biopsy could be undertaken, but in whom monoclonal gammopathies were present 
and  the  organ  distribution  of  amyloid  on  SAP  scintigraphy  was  characteristic  of  AL  type. 
Histology was performed with Congo red  followed by immunohistochemical staining; tissues 
examined were: kidney (n=26, 26%), endomyocardium (n=7, 7%), bone marrow (n=13, 13%), 
upper gastrointestinal tract (n=7, 7%), liver (n=3, 3%), fat (n=15, 15%), spleen (n=1, 1%), lung 
(n=1, 1%), rectum (n=9, 9%), soft tissues (n=12, 12% - included skin, tongue, buccal mucosa, 
labia), lymph node (n=3, 3%) and peritoneum (n=1, 1%). See figure 41 below: 
 
Figure 41: Pie chart showing distribution of tissue biopsies within the AL amyloidosis patient cohort 
(n=100). 
 
As described in chapter 7, all patients underwent 12 lead ECG, assays of the cardiac 
biomarkers NT-proBNP and Troponin T, and echocardiography at baseline. Mean ECG QRS 
voltage in limb and praecordial leads were calculated.
160 Echocardiographic assessment of 
diastolic  function  was  performed  as  described  in  section  7.8.  All  patients  underwent 
conventional CMR and EQ-CMR as previously described in sections 6.10 and 7.4. Standard Page 100 of 150 
CMR parameters of structure (LV mass, LAA, maximal septal thickness) and systolic function 
(EF, MAPSE, TAPSE) were assessed. Pre contrast myocardial values were calculated and the 
post contrast T1 map was performed at 15 minutes post bolus and after equilibration so that 
the ECVb and ECVi could be calculated.  
Some ECV data (n=19 of the 100) pre-dated the availability of ShMOLLI T1 mapping 
and had thus utilised multibreath-hold FLASH T1 measurement described in chapter 6.10. But 
as we have demonstrated equivalence of these ECVs in chapter 10, these patients are not 
excluded from the ECVi data.  
That said, these patients did not have an ECVb value or the subsidiary component of 
the ECV equation, pre contrast T1; multibreath-hold measurement has been shown to be 
inferior to T1 mapping, so accordingly, these were excluded from the sub-analysis comparing 
techniques - this particular analysis therefore consists of 81 rather than 100 patients.  
ECV  and  Myocardial  T1  results  were  compared  to  54  healthy  volunteers  who 
underwent pre contrast T1 mapping and ECV measurement (bolus and infusion).  The number 
of patients dead and alive was assessed after a median duration of 23 (Interquartile range: 6-
25) months. Some analysis involved sub-grouping patients into pre-test probability of cardiac 
involvement as previously described in section 7.2. All statistical analysis was performed as 
stated in section 7.11.  
 
12.4  Results: 
Table 6 on the next page summarises baseline characteristics for patients and healthy 
volunteers. Within the patient cohort, 14 (14%) patients were on treatment for hypertension; 
10 (10%) had confirmed coronary artery disease by angiography, 1 (1%) had had a stroke and 
2 (2%) had diabetes.  
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Characteristic:  Patients:  Healthy 
Controls: 
P value 
Male /female  62/30  25/29  P=0.02 
Mean Age ± SD (yrs)  62 ± 10  46 ± 15  P<0.001 
Mean Creatinine ± SD (mmol/L)  89 ± 33  74 ± 13  P<0.001 
Median NT-proBNP in pmol/L (IQ range)  146 (27-359)  -   
Median Troponin T in ng/L (IQ range)  0.03 (0.01-0.06)  -   
ECG/CMR indices 
Mean Indexed end-diastolic LV volume ± SD (mls)  60 ± 13  73 ± 12  P<0.001 
Mean Indexed end-systolic LV volume ± SD (mls)  19 ± 10  25 ± 7  P<0.001 
Mean EF ± SD (%)  67 ± 11  67 ± 6  P=0.42 
Mean Indexed LV mass ± SD(g/m
2)  97 ± 35  65 ± 15  P<0.001 
AF /atrial flutter (%)  6 (7)  0   
Table 6: Showing patient characteristics and differences between AL amyloidosis patients and healthy 
volunteers 
 
Fifty  patients  were  treated  with  chemotherapy  for  the  first  time  which  comprised 
triple  therapy  with  either  Cyclophosphamide,  Thalidomide  and  Dexamethasone  (CTD)  or 
Cyclophosphamide,  Velcade  and  Dexamethasone  (CVD),  depending  on  local  guidelines  of 
regional NHS Trusts within the UK. Seventeen patients were treated for a 2
nd or 3
rd time 
having relapsed – treatment was either with CVD or a Lenalidomide-containing regimen in 
these instances. Nine patients had not received any chemotherapy as there was no clinical 
indication  (e.g.  renal  amyloid  with  established  renal  failure,  isolated  neuropathic 
presentations) and 24 patients were under stable follow up with no indication for further 
chemotherapy at the time of scan.  
Twenty-one  patients  had  a  pre-test  probability  of  no  cardiac  involvement,  26  had 
possible cardiac involvement and 53 had definite cardiac involvement. 
All  ECV  values  are  the  ECVi  from  infusion  measurement  unless  otherwise  stated. 
Healthy controls were younger on average, but our work and others suggests any ECV changes 
with age are small compared to amyloid changes.
148,  165 There were proportionately more 
females in the control vs patient group. This slightly increases the control group ECV and pre Page 102 of 150 
contrast T1 compared to that of a gender matched group (male vs female: ECV 0.24 vs 0.27, 
P<0.001; T1 940 vs 966ms, P=0.006).   
 
ECV 
Myocardial T1 
Pre contrast  Post contrast 
LV Structure by CMR  R  P-value  R  P-value  R  P-value 
LV mass  0.48  P<0.001  0.43  P<0.001  0.40  P=0.004 
Indexed LV mass  0.50  P<0.001  0.43  P<0.001  0.36  P=0.01 
Septal thickness  0.61  P<0.001  0.53  P<0.001  0.34  P=0.01 
LA area  0.32  P=0.002  0.13  P=0.28  0.29  P=0.043 
Indexed LA area  0.30  P=0.005  0.09  P=0.45  0.14  P=0.31 
LV Systolic Function by CMR             
Ejection Fraction  0.48  P<0.001  0.32  P=0.005  0.20  P=0.17 
MAPSE  0.58  P<0.001  0.50  P<0.001  0.23  P=0.10 
LV end diastolic volume  0.06  P=0.58  0.12  P=0.30  0.09  P=0.51 
LV end-systolic volume  0.31  P=0.002  0.15  P=0.19  0.07  P=0.63 
Indexed LV end diastolic volume  0.10  P=0.32  0.17  P=0.14  0.25  P=0.07 
Indexed LV end systolic volume  0.32  P=0.002  0.14  P=0.24  0.01  P=0.93 
LV Diastolic Function by Echo             
E:E’   0.37  P<0.001  0.25  P=0.03  0.28  P=0.052 
IVRT  0.34  P=0.007  0.27  P=0.05  0.19  P=0.28 
E-Deceleration time  0.23  P=0.03  0.40  P<0.001  0.05  0.71 
RV Systolic Function by CMR             
TAPSE  0.57  P<0.001  0.52  P<0.001  0.41  P=0.003 
Biomarkers             
Serum NT-pro BNP (LnBNP)  0.65  P<0.001  0.58  P<0.001  0.25  P=0.07 
Troponin T (LnTropT)  0.52  P<0.001  0.36  P=0.02  0.62  P=0.001 
ECG             
ECG Limb Lead mean voltage  0.42  P<0.001  0.35  P=0.002  0.03  P=0.98 
ECG chest lead mean voltage  0.23  P=0.03  0.12  P=0.28  0.15  P=0.28 
Table 7: Showing the Pearson’s correlation coefficients and P values for the correlations of myocardial 
ECV, pre contrast T1 and post contrast T1 with standard cardiac parameters in patients with systemic 
AL amyloidosis.  
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As  in  chapter  8,  mean  cardiac  ECV  was  greater  in  patients  compared  to  healthy 
volunteers with a wider range (0.44 ± 0.12 vs 0.25 ± 0.02, P<0.001) and tracked pre-test 
probability  of  cardiac  involvement  by  conventional  parameters  (P<0.001).
150  Mean  pre 
contrast myocardial T1 values were raised in patients compared to healthy volunteers (1080 ± 
87 ms vs 954 ± 34ms, P<0.001) and also tracked pre-test probability of cardiac involvement 
(P<0.001).
185  Table 7 on the previous page provides the Pearson correlation coefficients of 
ECV, pre contrast and post contrast myocardial T1 compared to other cardiac parameters, 
many of which typically change in cardiac amyloid. ECV correlated significantly with 17 of 19; 
pre contrast T1 with 12, and post contrast T1 with 10. 
With regards late gadolinium enhancement, 25 patients had no LGE, 50 had global 
subendocardial  enhancement  and  10  had  extensive  enhancement.    Eight  had  patchy 
enhancement  and  7  had  evidence  of  only  altered  gadolinium  kinetics.  ECV  correlated 
significantly with increasing degrees of late gadolinium enhancement (P<0.001) as shown in 
figure 42 below. 
 
Figure 42: Dot plot showing correlation between ECV and late gadolinium enhancement 
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ECV correlates with survival: 
At follow up (median 23 months), 25 of 100 patients had died. For each potential 
predictor, median and tertile cut-points were assessed for predictive power using the Harrell’s 
C statistic and the best result presented (see table 8). 
  Tertile  Cut point  HR (95% CI)  P-value  Harrell’s C  
ECVi 
Tertile 1  0.40  4.67 (1.39 - 15.5)  0.013  0.63 
Median  0.45  3.83 (1.53 - 9.61)  0.004  0.66 
Tertile 2  0.49  3.61 (1.56 - 8.38)  0.003  0.65 
Pre contrast 
Myocardial T1 
Tertile 1  1044ms  5.39 (1.24 - 23.4)  0.02  0.64 
Median  1080ms  3.01 (1.08 - 8.44)  0.035  0.62 
Tertile 2  1116ms  3.22 (1.30 – 8.04)  0.01  0.63 
ECVb  Median  0.44  5.09 (1.09 – 23.7)  0.03  0.68 
Post contrast T1  Median  565ms  0.45 (0.17 – 1.20)  0.11  0.41 
Table 8: Showing the hazard ratios and P-values for the median / tertiles of ECVi, ECVb (median only), 
pre contrast T1 and post contrast T1 (median only). The Harrell’s C statistic is also shown (a value 
higher than 0.6 indicates a stronger discriminator).  
 
  For ECVi, a median ECV of 0.45 was the best model for assessing survival: HR 3.84 (1.53 
– 9.61), P=0.004 (figure 43 on the next page). The survival curve indicates that there is an 
approximately 40% chance of death at 23 months in patients with an ECV > 0.45 compared to 
15% for ECV < 0.45.  Page 105 of 150 
 
Figure 43: Kaplan Meier survival curve showing worse survival for patients with an ECVi > 0.45 
compared to patients with an ECVi < 0.45 in systemic AL amyloidosis. 
 
  For pre contrast myocardial T1, the 1st tertile (cut point 1044ms) was the best model: 
HR 5.39 (1.24 – 23.4), P=0.02 (figure 44A). ECVb with median of 0.44 also correlated with 
survival, with a HR of 5.09 (1.09-23.7), P=0.04 (figure 44B). Post contrast T1 did not correlate 
with survival (HR=0.5, P=0.11). 
 
 
Figure 44: Kaplan Meier survival curve showing worse survival for patients with (A) a pre contrast 
myocardial T1 of > 1044msec compared to patients with a T1 of <  1044msec and (B) an ECVb > 0.44 
compared to patients with an ECVb < 0.44 in systemic AL amyloidosis. 
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  When the 3 models (ECVi, ECVb and pre contrast T1) were compared to determine the 
best correlator with survival using the Harrell’s C statistic, all 3 performed similarly, although 
there  was  a  trend  to  suggest  ECVb  was  the  best  model  then  ECVi,  then  pre  contrast  T1 
(Harrell’s C statistics: 0.68, 0.65, 0.64 respectively, see also table 8 on page 104). 
  The time-dependent ROC curves  for t=12 months and t=24 months  using the NNE 
method are shown in figure 45. For comparison, time-dependent ROC curves by Kaplan Meier 
analysis for t=24 months are also shown in figure 46. At earlier follow-up times (t=12 months), 
the three ROC curves are not dissimilar and ECVi does not provide improved discrimination for 
cumulative mortality when compared to ECVb and pre contrast T1. At 24 months, they remain 
similar, although the NNE ROC curve for ECVi appears to dominate the ROC curves for both 
ECVb and pre contrast T1. This implies that, for any fixed specificity, the ECVi measurement at 
later follow up (t = 24 months) is a more sensitive marker. In contrast, the Kaplan Meier based 
ROC curves exhibit monotonicity violations. 
 
Figure 45: ROC curves for ECV and pre contrast myocardial T1 measurements against survival in AL 
amyloidosis at t=12 months and  t=24 months. Panels A-C show the ROC curves for t=12 months using 
the nearest neighbour estimator (NNE) and panels D-F show these for t=24 months. 
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Figure 46: Panels A-C show the ROC curves for t=24 months based on direct use of the simple Kaplan-
Meier estimator.  Comparison to the NNE-based ROC curves in figure 45 shows how KM-based ROC 
curves exhibit monotonicity violations. 
 
ECV independently predicts survival: 
  Table 9 below shows the univariate data for ECV with measures of systolic and diastolic 
function and serum biomarkers.  
Measure  HR (95% CI)  P-value 
ECV  3.84 (1.51-9.60)  P<0.001 
EF  0.95 (0.92-0.98)  P=0.001 
MAPSE  0.80 (0.71-0.90)  P=0.001 
TAPSE  0.81 (0.75-0.88)  P<0.001 
Indexed LVEDV  0.95 (0.92-0.99)  P=0.005 
Indexed LVESV  1.02 (0.98-1.06)  P=0.32 
NT-proBNP  5.80 (2.75-12.2)  P<0.001 
E:E’  1.09 (1.05-1.14)  P<0.001 
E-deceleration  time  1.00 (0.99-1.01)  P=0.29 
LGE  10.3 (1.39-76.5)  P=0.02 
ECG (limb)  0.92 (0.77-1.08)  P=0.35 
ECG (chest)  0.99 (0.97-1.02)  P=0.83 
Table 9: Showing hazard ratios and 95% confidence intervals for the univariate analyses of all 
measures against mortality. 
 
  After excluding collinearity (VIF < 3), ECVi > 0.45 remained significantly associated with 
mortality  (HR=4.41,  95%  CI  1.35-14.4;  P=0.01)  in  multivariate  Cox  models  that  included Page 108 of 150 
measures of systolic and diastolic function and serum biomarkers: E:E’, diastolic dysfunction 
grade (≥2), EF and LnNT-proBNP (Troponin was not available in all patients). E:E’ and NT-
ProBNP also remained independently predictive (see table 10 below). 
Measure  HR (95% CI)  P-value 
ECV  4.41 (1.35-14.4)  P=0.01 
EF  1.02 (0.98-1.07)  P=0.37 
E:E’  1.08 (1.02-1.15)  P=0.009 
NT-proBNP  4.41 (1.66-11.8)  P=0.003 
Diastolic dysfunction grade  0.31 (0.10-0.92)  P=0.03 
Table 10: Showing hazard ratios and 95% confidence intervals for the multivariate analysis for ECV, EF, 
E:E’, NT-proBNP and diastolic dysfunction grade against mortality. 
 
12.5  Discussion: 
Myocardial ECV in cardiac AL amyloid correlates with mortality. When dichotomised, a 
higher than mean ECV associates with roughly a 35-40% increased chance of death at 23 
months compared to lower ECV patients, despite therapy. Pre contrast T1 also correlated with 
survival.  Both  correlated  with  baseline  clinical  parameters.  In  practice,  since  the  two 
parameters  are  typically  measured  together,  their  combination  may  confer  diagnostic 
confidence.  
In chapters 8 and 11, I have previously described both ECV measurement and pre 
contrast T1 mapping as potential, non-invasive techniques for directly measuring the cardiac 
disease burden in AL amyloid.
150 Here, those earlier results are now strengthened by higher 
numbers and additionally, prognostic significance of the biomarkers is demonstrated even 
with therapy.   
The marked survival prediction power of ECV lends support to ECV as a key amyloid 
biomarker. Prior work in non-amyloid patients, where ECV likely measures diffuse fibrosis, has 
also showed predictive power – in  1176 consecutive CMR referral patients over a median of 
1.3 years follow up, 24 deaths occurred with ECV carrying a hazard ratio of 1.52 (1.21 – 1.89) 
for admissions with heart failure and all cause mortality.
199 Here, we have demonstrated that 
ECV  adds  incremental  value  over  and  above  existing  clinical  markers when  risk-stratifying 
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because this information was not available in all patients due to other factors limiting exertion 
such as peripheral and autonomic neuropathy due to systemic amyloidosis. Additionally, the 
limited  number  of  deaths  limits  very  extensive  multivariable  analysis  so  this  may  not 
represent the optimal multivariable model. 
We used an arbitrary categorization for the presence or otherwise of cardiac amyloid. 
The  Mayo  staging  system  is  the  most  recognized  predictor  of  survival  in  systemic  AL 
Amyloidosis.
33  In new  presentations,  median  survival  was  reduced  from  26  months to  10 
months when either NT-proBNP or Troponin T was raised and reduced further still to only 3 
months if both biomarkers were raised, although the authors are in the process of further 
refining this model with inclusion of values for serum free light chain concentration.
200 Our 
survival data in the 45 patients scanned at presentation would support these findings but is 
currently  underpowered  (only  17  deaths)  to  determine  incremental  benefit  of  ECV;  this 
remains work in progress.   
ECV is predictive regardless of treatment status and indeed irrespective of whether 
patients are presenting at diagnosis or years into the disease process. Some patients in the 
cohort  had  modest  ECV  increases  (ECV  0.30-0.40)  without  any  other  evidence  of  cardiac 
involvement (no LGE, no wall thickness increase and no biomarker elevation) reinforcing our 
original findings that even patients classified as having no cardiac amyloid do have raised ECVs 
suggestive  of  low  grade  cardiac  disease.  A  plausible  role  for  aggressive  therapy  in  such 
patients to prevent progression to overt cardiac disease can be entertained.
150  
The simpler, pre contrast myocardial T1 technique does not require a contrast agent 
and shows promise,
185 particularly as 20-30% of patients with systemic AL amyloidosis have an 
eGFR  <  30ml/min  at  presentation.  In  these  patients,  the  Mayo  staging  system  is  in  part 
confounded by elevation of serum biomarkers due to renal dysfunction. Here, pre contrast 
myocardial T1 by ShMOLLI is an alternative to ECV. It is an equally strong correlator with 
survival but as mentioned earlier, it represents a composite signal from cells and interstitium, 
not just the interstitium alone like ECV. Some work may be needed to derive normal pre 
contrast T1 values in patients with renal impairment due to non-amyloid related pathologies. 
An additional issue is that ECV measurement appears more independent of measurement 
approaches (magnet field strength, manufacturer, precise sequence details) and is likely to be 
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From a practical perspective, the bolus only approach to ECV (ECVb) was as good, if not 
better, a predictor of survival as the more cumbersome infusion ECVi. We showed in chapter 
10 (and indeed our group has shown that in most disease states) that ECVb carried excellent 
agreement with ECV at true equilibrium.
180 This study suggests that the ECVb passes a key 
clinical utility test of being prognostic.  Post contrast T1 however, was not useful either at 
baseline or to predict outcome.  
Limitations of the study are that patients were followed up for different time periods 
and are at different disease and treatment stages, with treatment here reflecting current UK 
practice.  Unfortunately,  the  cause  of  death  is not  always  known  in  these  patients  as  the 
National  Amyloidosis  Centre  only  generally  receives  notification  of  death  rather  than 
information on the formal cause of death. However, it is widely accepted that most death due 
to  AL  amyloidosis  are  cardiac  in  nature.  Studies  looking  to  correlate  ECV  change  with 
haematological and clinical response as well as histology in AL amyloidosis, have yet to be 
performed. Whole heart ECV calculations were not possible in this study because of through-
planing of blood pool in areas of thinner myocardium towards the apex but as technology 
advances  with  motion  correction  T1  mapping  sequences,  this  will  become  possible.  The 
advent of PSIR imaging is of growing importance in LGE imaging. As stated earlier, the number 
of events limits extensive analysis. That said, these are nevertheless hard endpoints and the 
rule of 10 regarding multivariable analysis can be relaxed in these settings.
201 Whether ECV 
and  pre  contrast  T1  –  which  are  not  entirely  concordant  -  provide  different  pathological 
insights is at this stage unknown.  
 
12.6  Conclusion: 
1.  ECV (ECVb and ECVi) tracks established disease, detects early cardiac involvement and 
independently correlates with survival.  
2. The pre contrast T1 mapping method is shown to be almost as prognostic, providing 
options for patients in renal failure.   
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13.  Pilot Study – Follow up EQ-CMR in Systemic AL Amyloidosis: 
This preliminary study, led by me, assessed the change in ECV amongst a small number of AL 
patients who we were able to re-scan when they re-attended the National Amyloidosis Centre 
a few months after their 1
st scan, for their follow up appointments. As the numbers were small 
at the time, this continues to be work in progress.  
 
13.1  Introduction: 
Change  over  time  in  cardiac  amyloid  is  not  well  understood.  The  way  myocytes 
hypertrophy or die and why such changes may be triggered by infiltration (or the free light 
chains) remain opaque. Treatment with chemotherapy or stem cell transplantation aims to 
reduce or eradicate abnormal circulating free light chains in order to reduce or stop further 
amyloid  production;  a  CR  is  associated  with  improved  morbidity  and  mortality.
135  The 
absence  of  systolic  and  diastolic  dysfunction  at  presentation  can  carry  a  much  more 
favourable  prognosis  than  once  thought.
202  If  light  chain  production  is  switched  off,  NT-
proBNP can fall nearly immediately despite no overt functional changes in the short term. 
Amyloid  regression  (well  described  in  AA  with  inflammation  switch  off)  does  not  occur 
substantially in the heart, although the liver and spleen may be more responsive.  
Our knowledge has been hampered by poor measurement. Wall thickness and LV mass 
measure myocytes and interstitium: changes may be reflective of either compartment and 
compensatory processes clearly occur, impeding understanding. Cardiac biopsy has shown 
regression of cardiac amyloid histologically but this is invasive.
203 We have demonstrated in 
this thesis how ECV can measure the interstitial expansion in multiple organs in systemic AL 
amyloidosis.  We  sought  to  explore  therefore  whether  ECV  could  detect  any  significant 
changes in organ amyloid burden at different time points in the disease.  
 
13.2  Hypothesis: 
  That ECV would change over time and with the success of therapy in AL amyloid.  
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13.3  Methods: 
  Of the 100 systemic AL patients, 26 were scanned a 2
nd time as described in section 7.2 
at one of their subsequent follow up appointments. As the patient follow up appointments 
are booked well in advance, it was not always possible to coincide an EQ-CMR scan as part of 
their next appointment because of the other clinically necessary investigations described in 
chapter 7. Hence, the follow up periods for each patient are different and  their “starting 
points” are all at different stages of disease. The median duration of follow up was 12 months.  
  All 26 patients were scanned with the identical protocol to their first scan and the ECVs 
for heart, liver and spleen were calculated. The patients were then categorised as follows: 
(1) Complete responders  - normal light chain levels (CR) throughout follow up (n=9) 
(2) Partial responders  - normal light chain levels for part of follow up period (n=8) 
     e.g. (a) commenced 6 months of chemo to CR; (b) Relapsed 
(3) Non-responders  - abnormal light chain levels throughout follow up (n=9) 
     e.g. (a) Failed to respond to chemo; (b) Stable PR 
  Mean difference in ECV for each organ was calculated for groups 1 to 3 and the results 
compared for statistically significant differences as described in section 7.11.  
 
13.4  Results: 
In group 1, there was a statistically significant improvement in LV mass, LA area and 
mean chest lead QRS voltage in patients who had normal light chains for the whole follow up 
period (see table 9). In terms of ECV, spleen ECV improved from 0.42 to 0.37 (P=0.02) but 
cardiac and liver ECV did not show any statistically significant changes.  
In group 2, there were no statistically significant changes, whilst in group 3, the LVEDV 
showed an improvement from 115ml to 94ml (P=0.04). These results are summarised in table 
11 on the next page: 
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  Responder 
group 
Baseline  Follow up  P-Value 
 
Myocardial T1 (msec) 
1  1089  1084  0.219 
2  1159  1101  0.125 
3  1080  1089  0.688 
 
Cardiac ECV 
1  0.43  0.40  0.300 
2  0.48  0.54  0.125 
3  0.52  0.57  0.500 
 
Liver ECV 
1  0.33  0.31  0.313 
2  0.38  0.36  0.813 
3  0.37  0.35  0.578 
 
Spleen ECV 
1  0.42  0.37  0.039 
2  0.58  0.47  0.439 
3  0.44  0.46  0.813 
 
ECG Limb Lead (mV) 
1  4.0  3.6  0.355 
2  4.8  4.8  0.893 
3  3.5  3.5  0.866 
 
ECG chest lead (mV) 
1  12.4  11.4  0.016 
2  12.4  11.7  0.152 
3  11.4  11.3  0.915 
 
LV mass (g) 
1  182  159  0.004 
2  212  198  0.301 
3  222  219  0.997 
 
Indexed LV mass (g/m
2) 
1  102  84  0.004 
2  103  97  0.310 
3  120  122  0.910 
 
LA area (cm
2) 
1  24  22  0.050 
2  31  30  0.931 
3  25  25  0.281 
 
Indexed LA area (cm
2) 
1  13  11  0.027 
2  15  15  0.930 
3  14  14  0.426 
Table 11: Showing the change in value from baseline to follow up of various markers of systemic AL 
amyloidosis, split according the responder status. P-values also shown.  
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When  the  overall  trend  was  considered,  a  scatter  plot  of  cardiac  ECV  changes 
suggested that generally, there was an improvement in ECV in patients with normal light 
chains (group 1) and a gradual worsening of ECV in the incrementally worse responder groups 
2  and  3  i.e.  an  apparent  downward  linear  trend  (see  figure  47);  however,  this  was  not 
statistically significant on formal linear regression analysis (P=0.132). Additionally, the Kruskall 
Wallis  test,  used  to  assess  the  distribution  of  cardiac  ECV  changes  across  the  responder 
groups, did not reveal a statistically significant result (P=0.356). 
 
Figure 47: Scatter plot of individual results showing change in myocardial ECV (y-axis) against 
responder status (x-axis) in systemic AL amyloidosis. (NB: some patients had exactly the same ECV, but 
still displayed as 1 point on the graph).  
 
Six patients in group 1, 7 in group 2 and all patients in group 3 had LGE at baseline. This 
did not qualitatively change at follow up (P=0.107).  
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Amyloid and cell mass were calculated as described in section 7.11 (baseline – follow 
up i.e. a +ve value denotes a decrease at follow up). Table 12 below shows the difference in 
amyloid mass and myocyte mass between the responder groups: 
Responder 
group 
Median amyloid mass 
difference in grams (IQ range) 
Median cell mass difference 
in grams (IQ range) 
1  +14.7 (+3 to +20)  +7.7 (+5 to +13) 
2  -3.2 (-14 to +8)  +17.6 (+6 to +28) 
3  -6.1 (-17 to +5)  +8.4 (0 to +11) 
Table 12: Showing the median difference from baseline to follow up in amyloid mass and myocyte cell 
mass across the 3 responder groups.  
 
When the trend across responder groups was analysed using the Kruskal Wallis test, 
the  difference  in  amyloid  mass  only  just  reached  statistical  significance  (P=0.05)  while 
difference in cell mass did not (P=0.305).  
 
13.5  Discussion: 
In  this  pilot  study,  26  patients  underwent  follow  up  EQ-CMR  scans  after  a  mean 
duration of 12 months and ECVs for heart, liver and spleen calculated. Group 1 demonstrated 
the most statistically significant changes, although other groups are confounded by a higher 
bias  of  death  and  therefore  not  reaching  follow  up,  a  limitation  common  to  all  studies 
assessing treatment response.  There was a higher risk of death in group 3 compared to group 
1  (HR  0.153,  P=0.014  for  group  1  by  Cox  regression  analysis)  in  keeping  with  current 
knowledge. Group 2 showed no statistically significant results. 
Spleen ECV showed an improvement from 0.42 to 0.37; cardiac and liver ECV changes 
did not reach statistical significance. These findings would suggest that the spleen may be a 
useful, early marker of disease response.  This may be because of an intrinsic property of 
splenic tissue that enables it to recover more readily from disease processes, similar to the 
liver.  Perhaps  because  embryologically-speaking,  the  spleen  is  a  primarily  haematological 
organ,  the  immune  system  is  more  readily  able  to  clear  amyloid  deposited  within  it. 
Considering that splenic tissue shows a higher range of ECV than the other organs (0.24 – 
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support to the theory that the spleen appears to be a more accurate marker of interstitial 
disease change systemic AL amyloidosis and this may be useful in pharmacological studies 
attempting to achieve amyloid regression. Histology would be necessary to confirm this. 
Group 1 also showed a statistically significant reduction in LV mass and LA area, both 
indexed  and  non-indexed.  One  could  speculate  that  this  is  due  to  a  reduction  in  the 
interstitium as there is a concomitant decrease in cardiac ECV, though again, cardiac histology 
is required to corroborate these suspicions. The reduction in LA area may represent a crude 
marker of improved diastology.  
Mean chest lead ECG voltage also showed a decrease from 12.4mV to 11.4mV in group 
1  (P=0.02).  This  might  be  reflective  of  a  reduction  in  LVH  with  a  sustained  complete 
haematological  response  as  there  is  corresponding  decrease  in  LV  mass  in  this  group. 
However, the long accepted theory has been that interstitial expansion explains the reduction 
in  QRS  voltages  as  electrical  activity  is  “insulated”  –  therefore,  any  suspected  amyloid 
regression should cause an increase in QRS voltage. So these findings raise questions about 
whether  the  interstitium  truly  insulates  electrical  activity  or  whether  in  fact  surface  ECG 
changes in amyloidosis reflect a balance between the source of the electrical activity (i.e. the 
myocytes) and the interstitium. 
In group 3 (the non-responder group), cardiac ECV rose from 0.52 to 0.57. Although 
this  did  not  reach  statistical  significance,  we  speculate  that  this  may  suggest  continued 
interstitial expansion due to ongoing amyloid deposits in the heart when patients do not 
achieve a CR. Interestingly, LV mass showed little change in this group, which might suggest 
myocyte necrosis at the expense of interstitial expansion, a potential mechanism to explain 
the worsening clinical status in this group; this should be explored further with histological 
studies, although as mentioned earlier, follow up studies in this non-responder group are 
generally hampered by the higher incidence of death 
There was a borderline statistically significant trend towards a regression in actual 
gram mass of amyloid with improving light chains. Albeit without histological support, this is 
the first evidence of regression of the interstitial expansion seen in systemic amyloidosis and 
provides  the  framework  for  developing  a  highly  accurate  marker  of  measuring  treatment 
response in the condition. Difference in cell mass did not reach statistical significance and it Page 117 of 150 
was not possible to assess differences in extra cardiac organs as the mass of these organs was 
not known.  
Clearly, the biggest limitation here is small numbers after categorising into 3 responder 
groups, as well as the bias towards death in  the groups who do not achieve a complete 
haematological response. There is also the issue of lead time bias as the patients were not 
followed up for the same amount of time or from the same point in the disease process so it is 
difficult to draw many meaningful conclusions. A further limitation, common to the whole 
thesis, is the lack of corroborating evidence from histological studies. However, we are able to 
detect some changes in the different responder groups and these findings have potential to 
provide further insights into the biological mechanisms underlying the disease process in AL 
amyloid. The clinical relevance of these findings is once again emphasised when one considers 
the in vitro data and now the ongoing human trials of the dual CPHPC-monoclonal antibody 
trial.  
 
13.6  Conclusion: 
ECV  may  represent  the  initial  stages  of  the  first  non-invasive  tool  to  demonstrate 
amyloid regression and progression in systemic AL amyloidosis. 
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14.  DISCUSSION AND CONCLUSIONS 
 
14.1  Background and Hypotheses Explored: 
Cardiac amyloidosis remains challenging to diagnose and to treat.  Key ‘red-flags’ that 
should raise suspicion include clinical features indicating multisystem disease and concentric 
LV thickening on echocardiography in the absence of increased voltage on ECG;  the pattern of 
gadolinium enhancement on CMR appears to be very characteristic.  Confirmation of amyloid 
type is now possible in most cases through a combination of immunohistochemistry, DNA 
analysis and proteomics.  
But  whilst  developments  in  chemotherapy  have  improved  the  outlook  in  AL 
amyloidosis, the prognosis of patients with cardiac involvement remains very poor and senile 
cardiac amyloidosis is probably greatly under-diagnosed. Although a variety of novel specific 
therapies are on the near horizon, with potential to both inhibit new amyloid formation and 
enhance  clearance  of  existing  deposits,  current  treatment  remains  mainly  supportive, 
focussed on diuretic therapy.  
The inability to reconcile advances in treatment strategies with improved outcomes 
reflects our incomplete understanding of the biology of the disease process. For example, 
whilst well recognised, it is not known why cardiac ATTR amyloidosis is better tolerated than 
cardiac  AL  amyloidosis,  despite  the  much  thicker  hearts?  Or  why  exactly  ECGs  show  low 
voltages in the limb leads? A number of theories have been put forward e.g. myocyte necrosis 
in AL amyloidosis, or toxicity from circulating immunoglobulin light chains, or an acute (e.g. 
myocardial oedema) on chronic process in advanced stages of cardiac AL Amyloidosis, but 
none has ever been definitely proven.  
This is likely because no technique has been thus far able to feasibly image or quantify 
the interstitium in this archetypal interstitial disease. Being able to do so would undoubtedly 
improve our knowledge of the differences between amyloid types and may allow therapy to 
be better targeted. Recently, MRI and more specifically, EQ-CMR has been shown to measure 
the interstitium in a variety of cardiac diseases.  
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As a result of the work during my MD: 
1) I have demonstrated that ECV measurement in Systemic Amyloidosis is feasible and I have 
refined the technique as described in chapter 10 to make it clinically more applicable.  
2) I have defined a reference range of ECVs that track increasing levels of cardiac disease 
within the amyloidosis population as well as in multiple other organs.  
3) I have applied the pre contrast myocardial T1 technique to assess amyloid deposition in the 
heart, which will have a role in the 25-30% of AL amyloidosis patients with eGFR < 30ml/min 
where gadolinium administration would be relatively contraindicated.  
4) I have shown how ECV and T1 correlate with mortality in this disease and demonstrated 
that clinical outcome may be changed by identifying those patients who may benefit the most 
from early treatment.  
 
14.2  Refining Clinical Applicability of EQ-CMR in Systemic Amyloidosis: 
Before  the  work  in  this  thesis,  measurement  of  the  ECV  technically  required 
equilibration  of  contrast  concentrations  between  blood  and  myocardium,  which  can  be 
achieved precisely  using  a  somewhat  cumbersome  primed  contrast  infusion  (ECVi).
147  The 
patient would have to undergo a 30 minute infusion of gadolinium contrast which was very 
disruptive to clinical workflow and quite tedious and cumbersome for a population of patients 
who are particularly unwell. We found that it was only possible to scan 6 patients per day 
using this method, whereas our clinical CMR list currently scans 10 patients in the same time 
frame – a significant financial burden. Additonally, the FLASH IR method of T1 measurement 
required  9  breath-holds  before  and  after  contrast  administration,  each  lasting  around  14 
seconds to acquire a map of a single slice. It is also not an accurate method for evaluation of 
tissues with longer T1, particularly that of blood prior to contrast administration.  
During  my  MD,  we  entered  into  a  collaboration  with  the  Oxford  group,  who  had 
written a new T1 mapping sequence, the ShMOLLI. This allows a T1 map of a selected slice to 
be generated in a single breath-hold over 9 heart beats. We found it to be faster and more 
reproducible than the the FLASH IR method in amyloidosis. By applying this technique to EQ-
CMR in chapter 10 and validating its use in calculating ECV in systemic amyloidosis, what Page 120 of 150 
previously took 8-10 mins now takes under 1 minute as a result of my work. Similarly, I have 
shown in chapter 10 that ECV can be calculated sufficiently accurately  through delayed study 
following administration of a bolus of gadolinium (ECVb).
180 As a result of this work, the overall 
scan time is reduced by a further 30 minutes, making the scan clinically more applicable.  
Both of these advances have made the assessment of ECV a much simpler “add on” to 
a clincal CMR scan, only requiring in addition, a haematocrit measurement. 
 
14.3  ECV Measurement: 
Before  my  work,  there  was  no  non-invasive  quantifier  of  interstitial  expansion  in 
systemic amyloidosis. There had been some work assessing interstitial expansion in other 
disease using different models such as partition coefficients and dynamic contrast-enhanced 
MR.  
My work has now demonstrated that ECV can be calculated in the basal to mid septum 
in  cardiac  AL  amyloidosis  and  it  shows  a  large  increase  in  the  myocardium. ECV  Disease-
specific correlations have been identified. The technique was also used to assess the liver, 
spleen and biceps ECV in amyloidosis patients healthy volunteers as well as a preliminary 
evaluation of its role in tracking disease progress or improvement at follow up.  
Novel information has also been gained as a result of this work as I showed in chapter 
8 that when ROIs are drawn in LGE positive and LGE negative areas in the same patient, the 
ECV, whilst lower in LGE negative areas, is still not normal.
150 Because of this, although T1 
mapping  is  now  more  mature  with  sequences  available  on  all  platforms,  it  is  difficult  to 
compare ECV and T1 to LGE and PSIR imaging which can be helpful with LGE imaging in 
amyloid, is not available on all platforms.  
 
14.4  Native Myocardial T1: 
Prior to my work, there had been only case reports of T1 analysis using the Look-
Locker method to assess T1 times in cardiac amyloidosis. The Look Locker method is prone to 
error because of long breath-hold times, T1 measurements in different phases of the cardiac 
cycle and being more T1 and heart-rate dependent.  Page 121 of 150 
My work has provided reference ranges for myocardial T1 times in cardiac amyloidosis 
using the more robust T1 mapping sequence, the ShMOLLI. We found a large increase in pre 
contrast T1 values in patients with increasing amyloid deposition. This work has opened up 
the door to non-invasive analysis of amyloid burden by cardiac MR in patients with renal 
failure  which  was  hitherto  not  possible  because  of  the  risk  of  NSF  from  gadolinium.  The 
combination of this with ECV has provided information on some of the biology in AL amyloid. 
 
14.5  Clinical Insights and Potential: 
Although  trends  are  changing,  assessment  of  cardiac  amyloidosis  currently  relies 
predominantly on echocardiography which, as an imaging modality, has a much lower spatial 
resolution than MRI. The main determinants of severity are septal thickness and LV mass, 
which incompletely reflect the biology at work and systolic / diastolic dysfunction which likely 
represent more advanced stages of the disease.  
The ECV shows the potential to fill this gap not only for the heart, but also the liver and 
spleen and may permit earlier identification of cardiac disease which may save lives. The pilot 
studies suggest possible biological explanations for some hitherto unexplained observations 
(e.g.  low  QRS  voltages  on  ECG)  and  also  speculate  upon  the  role  of  ECV  in  monitoring 
response  to  therapy.  But  most  importantly,  it  has  the  potential  to  be  an  independent 
predictor of survival, additive to current prognosticators such as the Mayo classification. This 
would save patient lives not only from the disease itself, but possibly even reduce some of the 
treatment-related mortality.  
However, it is important to balance this with recognition of the current limitations. I 
have not been able to histologically validate the technique so the technique cannot yet be 
deemed to be a true non-invasive quantifier of cardiac amyloid burden. Removal of the need 
for a gadolinium infusion has made the technique more clinically applicable as a diagnostic 
tool. However, debate remains whether ECVb would be sufficiently accurate for follow up and 
monitoring of disease progression.  
Furthermore, although ECV has emerged as independently predictive of survival in 
multivariate analysis, it is unclear how much this will impact on and change current clinical 
management which relies heavily on Troponin T and NT-pro BNP; if one considers ECV as a Page 122 of 150 
biomarker, it is more expensive than Troponin T and NT-pro BNP although if one considers the 
additional information gained from cardiac MRI as a whole with ECV as an add-on, this may 
represent a more cost-effective strategy overall – further studies are needed. There are also 
standardisation challenges yet to be addressed across different centres with MRI.  
 
14.6  Future Work: 
This thesis has looked at the diverse uses of CMR T1 mapping based methodology to 
assess systemic amyloidosis. Work is needed to establish histological validation of ECV with 
cardiac histology. This is challenging not only because of the obvious invasive nature of biopsy, 
but also because of the need to correlate the timing of biopsy within an acceptable time-
frame of the EQ-CMR scan, something which is not easy when patients live so far away. The 
ideal  staining  method  to  differentiate  amyloid  from  fibrosis  in  a  manner  which  is  still 
quantifiable by computer software remains an ongoing challenge too.  
ECV  measurements  in  extracardiac  organs  also  requires  standardising.  The  ideal 
method of T1 mapping the liver and spleen remains undetermined and where to draw ROIs in 
the liver requires universal agreeement. Further work is also needed in evaluating the role of 
ECV and T1 in ATTR amyloidosis – this is already work in progress.  
From an MRI perspective, the T1 mapping sequences are constantly improving e.g. the 
ShMOLLI sequence currently does not correct for any motion artefacts which makes it more 
likely  to  result  in  partial  voluming  with  blood  at  the  edges  of  a  myocardial  ROI  –  such 
sequences  are  work  in  progress.
204  There  has  also  been  very  little  work  comparing  the 
reproducibility  T1  and  ECV  across  multiple  sites  and  using  MRI  equipment  from  differing 
vendors. 
From a more general perspective, myocardial T1 and ECV assessment is a new field 
and there is little agreement between groups as to what terminology should be used e.g. 
extracellular  volume  (ECV),  extracellular  volume  fraction  (ECVF),  myocardial  volume  of 
distribution (Vd(m)) have all been used by different groups to describe the same thing over the 
last 2-3 years. An initiative from this hospital (Prof. James Moon) has therefore set up a T1 
mapping  development  group  which  has  now  met  7  times  and  has  drafted  proposed 
preliminary recommendations for everyone in the field to use as a baseline guide.  Page 123 of 150 
My work has triggered a number of key changes and progressions, specifically: 
1.  The NAC now routinely transfers patients to the Heart Hospital for CMR scanning and T1 
mapping to calculate ECV which was not previously the case.  
2.  ECV results now play a key role in the weekly MDT meetings when determining the timing 
and choice of treatment.  
3.  My work comparing ECV to SAP scanning in AL amyloidosis has laid the groundwork for 
similar research in comparing ECV with DPD scanning in ATTR amyloidosis. This work has 
already begun and the preliminary findings were shortlisted at the Young Investigator 
Awards at the 2014 AHA scientific sessions in Chicago, USA.  
4.  My work with ECV in the liver and spleen in AL amyloidosis has attracted the attention of 
the pharmaceutical industry who are now using ECV of the liver and spleen as an endpoint 
for  their  first  in  man  study  of  therapy  in  systemic  AL  amyloidosis,  following  my 
presentation of this data at the International Amyloidosis Symposium in 2012.  
 
14.7  Conclusion: 
This thesis has provided further insight into the field of myocardial T1 mapping and 
ECV  assessment  and  highlighted  their  roles  in detecting  cardiac  and  systemic  amyloidosis 
involvement at a much earlier stage and also more sentivitively. It shows the huge potential of 
these techniques and lays a path for future work in the field to ultimately benefit and improve 
patient outcomes from this rare but fatal disease.   Page 124 of 150 
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